Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
>>> Scientists Heal Paralyzed Mice With Spinal Cord Implants
NeoScope
FEB 7, 2022
BY ABBY LEE HOOD
https://futurism.com/neoscope/scientist-mice-spinal-cord
"IF THIS WORKS IN HUMANS, AND WE BELIEVE THAT IT WILL, IT CAN OFFER ALL PARALYZED PEOPLE HOPE THAT THEY MAY WALK AGAIN."
Nearly every paralyzed mouse scientists operated on in a new experiment were able to walk normally after receiving spinal cord implants.
But will it work for humans? Researchers released a new study in the journal Advanced Science this morning, and they’re saying the work may indeed have implications in human medicine.
“If this works in humans, and we believe that it will, it can offer all paralyzed people hope that they may walk again,” the research team at the Sagol Center for Regenerative Biotechnology told the Times of Israel, adding that the team has started discussing clinical trials with the US Food and Drug Administration.
The experiment took place at Tel Aviv University where the team, led by Professor Tal Dvir, engineered spinal cord tissue from human cells and implanted them into mice with long-term paralysis. Of the 15 mice they operated on, 12 were able to walk normally.
Dvir told the Times of Israel that the mice received spinal implants from cells of multiple people, but for human patients the plan would be to grow a unique spine for each using their own body’s cells. If approved, the study’s authors wrote in their conclusions that a personalized hydrogel would be created to implant into patients.
Of course, it’s always unclear whether an animal-tested therapy will work in humans. In 2020 Harvard published a report on the multitude of reasons why medicines tested in mice often fail in human trials. Part of the problem is that even though humans and mice share some genes, according to the National Human Genome Research Institute, they function in the cells in different ways. Of the hundreds of Alzheimer’s treatments that work on mice, the Harvard report states, none work on people.
“If we were all mice, Alzheimer’s disease, cancer, diabetes, and most inherited disorders would be a thing of the past,” reads the report.
However, the Tel Aviv experiment isn’t a pill or drug. And scientists did just successfully pull off a heart transplant in which a man received a genetically modified pig heart. Anything is possible, if not probable, and helping paralyzed people walk again would be a pretty amazing feat if this team pulls it off.
<<<
>>> MeaTech Reveals Promising Results with Muscle Stem-Cell Differentiation
Yahoo Finance
February 8, 2022
https://finance.yahoo.com/news/meatech-reveals-promising-results-muscle-120000941.html
Successful development of novel technology process fusing muscle cells into significant muscle fibers that better resemble those in whole cuts of meat
NESS ZIONA, Israel, Feb. 8, 2022 /PRNewswire/ -- MeaTech 3D Ltd., (NASDAQ-CM: MITC), an international food technology company at the forefront of the cultured meat industry, today revealed significant improvement in its differentiation process from stem cells to muscle fibers. The company has succeeded in accelerating the formation of real living muscle fibers and enhancing their quality to mirror key characteristics of farm-raised meat.
These results show the process in which bovine stem cells were isolated, proliferated in the lab, and differentiated into matured muscle cells with improved muscle fiber density, thickness and length. Based on these improvements, MeaTech has filed a provisional patent application with the USPTO.
Arik Kaufman, CEO of MeaTech: "Today's achievement is another important step towards our goal of developing a true replacement for conventional meat. We are committed to advancing our cellular technology to attain a cultivated-meat-eating experience that replicates that of farm-raised meat. This achievement follows our recent announcement that we successfully 3D printed an almost 4 oz steak comprised of actual living muscle and fat tissue."
Yaron Kaiser, Chairman of the Board, MeaTech: "MeaTech's wonderful results, led by our technology team, place the company at the forefront of the cultured meat revolution.
The professionalism and capabilities of a small, elite, and goal-oriented technological team are enabling MeaTech to achieve significant and groundbreaking achievements efficiently and quickly, giving the company a clear competitive advantage in an industry that is on a secure path to changing our lives and the way we consume meat. "
About MeaTech 3D
MeaTech is an international food technology company at the forefront of the cultured meat revolution. The company is listed on the Nasdaq Capital Market under the ticker "MITC".
MeaTech initiated activities in 2019 and maintains facilities in Ness Ziona, Israel and Antwerp, Belgium. The company believes cultivated meat technologies hold significant potential to improve meat production, simplify the meat supply chain, and offer consumers a range of new product offerings.
MeaTech aims to provide an alternative to industrialized animal farming, circumventing the serious issues surrounding conventional animal husbandry, such as carbon footprint, water resources and animal welfare. By adopting a modular factory design, MeaTech will be able to offer a sustainable solution for a variety of species, including beef, chicken, and pork, both as raw materials and whole cuts; and also provide the production equipment
<<<
>>> What We Learned About Pegasus, the Smartphone Cracker
https://s.yimg.com/os/creatr-uploaded-images/2022-01/d23992d0-8045-11ec-bfff-88b2e06cfdc7">https://s.yimg.com/os/creatr-uploaded-images/2022-01/d23992d0-8045-11ec-bfff-88b2e06cfdc7" />
This studio photographic illustration shows a smartphone with the website of Israel's NSO Group which features 'Pegasus' spyware, on display in Paris on July 21, 2021. - Private Israeli firm NSO Group has denied media reports its Pegasus software is linked to the mass surveillance of journalists and rights defenders, and insisted that all sales of its technology are approved by Israel's defence ministry.
New York Times
by Michael Levenson
January 28, 2022
https://www.yahoo.com/news/learned-pegasus-smartphone-cracker-133036366.html
It is widely regarded as the world’s most potent spyware, capable of reliably cracking the encrypted communications of iPhone and Android smartphones.
The software, Pegasus, made by an Israeli company, NSO Group, has been able to track terrorists and drug cartels. It has also been used against human rights activists, journalists and dissidents.
Now, an investigation published Friday by The New York Times Magazine has found that Israel, which controls the export of the spyware, just as it does the export of conventional weapons, has made Pegasus a key component of its national security strategy, using it to advance its interests around the world
The yearlong investigation, by Ronen Bergman and Mark Mazzetti, also reports that the FBI bought and tested NSO software for years with plans to use it for domestic surveillance until the agency finally decided last year not to deploy the tools.
The Times found that sales of Pegasus played a critical role in securing the support of Arab nations in Israel’s campaign against Iran and negotiating the Abraham Accords, the 2020 diplomatic agreements, signed at a Trump White House ceremony, that normalized relations between Israel and some of its longtime Arab adversaries.
The U.S. sought the cyberweapon for domestic use.
The U.S. had also moved to acquire Pegasus, the Times found. The FBI, in a deal never previously reported, bought the spyware in 2019, despite multiple reports that it had been used against activists and political opponents in other countries. It also spent two years discussing whether to deploy a newer product, called Phantom, inside the United States.
The discussions at the Justice Department and the FBI continued until last summer, when the FBI ultimately decided not to use NSO weapons.
But Pegasus equipment is still in a New Jersey building used by the FBI. And the company also gave the agency a demonstration of Phantom, which could hack American phone numbers.
A brochure for potential customers, obtained by the Times, says that Phantom allows American law enforcement and spy agencies to “turn your target’s smartphone into an intelligence gold mine.”
The yearlong Times investigation was based on interviews with government officials, leaders of intelligence and law enforcement agencies, cyber experts, business executives and privacy activists in a dozen countries.
It tells the story of NSO’s rise from a startup operating out of a converted chicken coop on an agricultural cooperative to its blacklisting by the Biden administration in November because of its use by foreign governments to “maliciously target” dissidents, journalists and others.
NSO began with two school friends, Shalev Hulio and Omri Lavie, hatching startups in Bnai Zion, an agricultural cooperative outside of Tel Aviv, Israel, in the mid-2000s.
One of their startups, CommuniTake, which offered cellphone tech-support workers the ability to take control of their customers’ devices — with permission — caught the attention of a European intelligence agency, Hulio said.
NSO was born, and the company eventually developed a way to gain access to phones without the user’s permission — no need to click on a malicious attachment or link. (That the company’s name sounded like the NSA was a mere coincidence).
‘You start to believe your every move is watched.’
After NSO began selling Pegasus globally in 2011, Mexican authorities used it to capture Joaquín Guzmán Loera, the drug lord known as El Chapo. And European investigators used it to smash a child-abuse ring with dozens of suspects in more than 40 countries.
But abuses have also been revealed in reports by researchers and news organizations, including the Times.
Mexico used the spyware to target journalists and dissidents. Saudi Arabia used it against women’s rights activists and associates of Jamal Khashoggi, the Washington Post columnist who was killed and dismembered by Saudi operatives in 2018.
That year, the CIA bought Pegasus to help Djibouti, a U.S. ally, fight terrorism, despite long-standing concerns about human rights abuses there, including the persecution of journalists and the torture of dissidents.
In the United Arab Emirates, Pegasus was used to hack the phone of an outspoken critic of the government, Ahmed Mansoor.
Mansoor’s email account was breached, his geolocation was monitored, $140,000 was stolen from his bank account, he was fired from his job and strangers beat him on the street.
“You start to believe your every move is watched,” he said. In 2018, he was sentenced to 10 years in prison for posts he made on Facebook and Twitter.
Through a series of new deals licensed by the Israeli Ministry of Defense, Pegasus has been provided to the far-right leaders of Poland, Hungary, India and other countries.
Then-Prime Minister Benjamin Netanyahu did not order the Pegasus system to be cut off, even when the Polish government enacted laws that many Jews inside and outside of Israel saw as Holocaust denial, or when Prime Minister Mateusz Morawiecki, at a conference attended by Netanyahu himself, falsely listed “Jewish perpetrators” among those responsible for the Holocaust.
The blacklisting of NSO infuriated Israeli officials.
American companies have been trying to build their own tools that could hack phones with the ease of NSO’s “zero click” technology.
One of those companies, Boldend, told Raytheon, the defense-industry giant, in January 2021, that it could hack WhatsApp, the popular messaging service owned by Facebook, but then lost the capability after a WhatsApp update, according to a presentation obtained by the Times.
The claim was especially notable because, according to one of the slides, a major Boldend investor is Founders Fund — a company run by Peter Thiel, the billionaire who was one of Facebook’s first investors and remains on its board.
The recent U.S. blacklisting of NSO could suffocate the company by denying it access to the American technology it needs to run its operations, including Dell computers and Amazon cloud servers.
The rebuke has infuriated Israeli officials who have denounced the move as an attack not only on a crown jewel of the country’s defense industry but on the country itself.
“The people aiming their arrows against NSO,” said Yigal Unna, director general of the Israel National Cyber Directorate until Jan. 5, “are actually aiming at the blue and white flag hanging behind it.”
<<<
>>> Israeli alt-meat developer MeaTech prints 3.67 oz steak
Jerusalem Post
By ZACHY HENNESSEY
12-8-21
https://www.msn.com/en-us/news/technology/israeli-alt-meat-developer-meatech-prints-367-oz-steak/ar-AARBNC4?ocid=uxbndlbing
Israel-based MeaTech 3D has succeeded in bioprinting a 104-gram (3.67-oz.) cultivated steak, primarily composed of real cultivated fat and muscle cells. This is, according to the company, the largest cultivated steak comprised of real, living muscle and fat tissues, without using any soy or pea protein.
MeaTech’s achievement serves as a milestone toward the goal of scaled production of cultivated bioprinted steak.
“Today’s breakthrough is the culmination of over one year’s efforts in our cellular biology and high-throughput tissue engineering processes, as well as our precision bioprinting technology,” said Sharon Fima, MeaTech CEO and CTO. “By bioprinting a 3.67-oz. steak composed of living tissue, we believe we have both validated our core technologies and placed ourselves at the forefront of the race to develop high-end, real cell-based cultivated premium meat products.”
MeaTech’s goal is developing a true replacement for conventional steak that maximizes cell-based content rather than nonmeat ingredients. “The technology that MeaTech is developing is designed to be an enabler: to supply real meat solutions that are sustainable, safe and ethical,” said Omri Schanin, MeaTech co-founder and deputy CEO. “With demand rising, it is our mission to make meat widely accessible around the world, which is why we aim for price parity to conventional meat as you know it today.”
MeaTech employed in-house-developed 3D bioprinting technology and advanced tissue engineering science in order to bring sustainable, premium cultivated meat products closer to the market.
The cells used in making the steak were produced using an advanced and proprietary process that starts by isolating bovine stem cells from tissue samples and multiplying them. Upon reaching sufficient cellular mass, stem cells were formulated into bio-inks compatible with MeaTech’s proprietary 3D bioprinter. The product, printed from a digital design file of a steak structure, was then matured in an incubator, where the printed stem cells were differentiated into fat and muscle cells that develop into fat and muscle tissue, respectively, to form the MeaTech steak.
The next step for the alternative-meat company is to get its product on shelves.
“Our go-to-market plan starts with non-printed meat, such as hybrid products containing cultured real fat, for better taste and texture in this exploding meat alternative industry,” explained Schanin. “Next year we plan to open a pilot plant that produces cultured fat for this purpose, with the aim of hitting the market as soon as possible.”
MeaTech is currently scaling up its manufacturing process by initiating operation of its semi-industrial printer next year.
Schanin pointed out that, to them, the time to get the ball rolling on production is as soon as possible. “I think people have not yet realized what enormous potential this industry has.”
<<<
>>> U.S. blacklists Israeli hacking tool vendor NSO Group
Reuters
By Christopher Bing
https://www.reuters.com/technology/us-blacklists-four-companies-israel-russia-singapore-citing-spyware-2021-11-03/
WASHINGTON, Nov 3 (Reuters) - The U.S. Commerce Department added Israel's NSO Group and Candiru to its trade blacklist on Wednesday, saying they sold spyware to foreign governments that used the equipment to target government officials, journalists and others.
Positive Technologies of Russia, and Computer Security Initiative Consultancy PTE LTD, from Singapore, were also listed. The Department said they trafficked in cyber tools used to gain unauthorized access to computer networks.
The companies' addition to the list, for engaging in activities contrary to U.S. national security or foreign policy interests, means that exports to them from U.S counterparts are restricted. It for instance makes it far harder for U.S. security researchers to sell them information about computer vulnerabilities.
"We are not taking action against countries or governments where these entities are located," said a spokesperson for the U.S. State Department.
Suppliers will need to apply for a license before selling to them, which is likely to be denied.
In the past, the NSO Group and Candiru have been accused of selling hacking tools to authoritarian regimes. NSO says it only sells its products to law enforcement and intelligence agencies and takes steps to curb abuse.
'DISMAYED'
An NSO spokesperson said the company was "dismayed" by the decision since its technologies "support U.S. national security interests and policies by preventing terrorism and crime, and thus we will advocate for this decision to be reversed."
NSO will present information regarding its "rigorous" compliance and human rights programs, "which already resulted in multiple terminations of contacts with government agencies that misused our products," the spokesperson said in an e-mailed statement to Reuters.
The Israeli defence ministry, which grants export licenses to NSO, declined to comment on the matter.
Contact information for Candiru was not available.
The Biden administration imposed sanctions on Positive Technologies, a Russian cybersecurity firm, this year for providing support to Russian security services. The company denies any wrongdoing.
Positive Technologies said the new sanctions will not affect their business and will not prevent the company from a planned public listing.
"We do not know on what grounds the U.S. Commerce Department added us to the list," General Director Denis Baranov said in an emailed comment.
"Anyway we repelled sanction risks earlier and they do not pose additional threats for us now," he wrote.
Computer Security Initiative Consultancy PTE LTD, also known as COSEINC, did not immediately respond to requests for comment.
A former U.S. official familiar with Positive Technologies, who spoke on condition of anonymity, said the firm had helped establish computer infrastructure used in Russian cyberattacks on U.S. organizations.
COSEINC founder Thomas Lim is known for organizing a security conference, named SyScan, which was sold to Chinese technology firm Qihoo 360, a sanctioned entity. An email published by WikiLeaks in 2015 suggested Lim had also previously offered to sell hacking tools to infamous Italian spyware vendor HackingTeam.
Lim did not immediately respond to a request for comment sent to a social media account he owns.
Export control experts say the designation could have a far broader impact on the listed companies than simply limiting their access to U.S. technology.
"Many companies choose to avoid doing business with listed entities completely in order to eliminate the risk of an inadvertent violation and the costs of conducting complex legal analyses," said Kevin Wolf, former assistant secretary of Commerce for Export Administration during the Obama administration.
The entity list was increasingly used for national security and foreign policy aims during the Trump administration. Chinese telecom company Huawei (HWT.UL) was added in 2019, cutting it off from some key U.S. suppliers and making it difficult for them to produce mobile handsets.
<<<
Groundwork BioAg - >>> GrowGeneration Signs Distribution Agreement with Groundwork BioAg
Yahoo Finance
October 7, 2021
https://finance.yahoo.com/news/growgeneration-signs-distribution-agreement-groundwork-123000368.html
Expands nutrient and additive portfolio to include leading mycorrhizal inoculant DYNOMYCO via online superstore and retail locations.
DENVER, Colo. and MAZOR, Israel, Oct. 7, 2021 /PRNewswire/ - GrowGeneration Corp. (NASDAQ: GRWG) ("GrowGen") the nation's largest chain of specialty hydroponic and organic garden centers, and Groundwork BioAg, a global bio-agriculture company, today announced that they have entered into a distribution agreement to offer DYNOMYCO®, a unique brand of highly-concentrated mycorrhizal inoculants specifically formulated for cannabis, to hydroponic and organic growers across the U.S. Representing two of the fastest growing segments in agriculture – cannabis and biologicals – the distribution agreement brings together GrowGen's commercial reach and marketing prowess with Groundwork BioAg's innovative and highly-effective mycorrhizal inoculants.
DYNOMYCO has exhibited strong efficacy in cannabis, with yield increases of 10%-45%, as well as increased cannabinoid content. DYNOMYCO also reduces dependency on phosphorus fertilizer, improves nutrient uptake, and reduces transplantation shock. Mycorrhizae are a cornerstone of regenerative agriculture best practices, and a key to maintaining plant root health in horticulture.
"Product portfolio expansion has become a strategic priority for GrowGen, and a key component of our long-term revenue generation plan," said Paul Rutenis, GrowGen's Chief Merchant Officer. "We are proud to bring Groundwork BioAg's unique technologies and proprietary mycorrhizal products to GrowGen and our family of growers who are on the leading edge of farm management practices to produce the highest quality plants."
Following 30 years of research and product development, DYNOMYCO is highly-concentrated and formulated for convenient application and efficacy on cannabis plants and is suitable for individual growers and large commercial farms alike. The product is suitable for organic cultivation and is certified by Clean Green, Organic Materials Review Institute (OMRI), and California Department of Food and Agriculture Organic Input Material Program (CDFA-OIM).
"Through our partnership with GrowGen, one of the most respected names in hydroponic and organic gardening, we are able to ensure growers have access to our unique formulation of mycorrhizal inoculants for maximum performance," said Dan Grotsky, Co-Founder and Chief Growth Officer of Groundwork BioAg, and DYNOMYCO's General Manager. "DYNOMYCO continues to gain tremendous momentum among cannabis growers. Through this strategic partnership, we can ensure growers across the nation have easy access to a product they love from a retailer they trust."
Starting in October 2021, growers will be able to purchase DYNOMYCO directly from GrowGen's 62 retail hydroponic and organic garden centers or on GrowGeneration's online superstore: www.growgeneration.com.
About GrowGeneration Corp.:
GrowGen owns and operates specialty retail hydroponic and organic gardening stores. Currently, GrowGen has 62 stores, which include 24 locations in California, 8 locations in Colorado, 7 locations in Michigan, 5 locations in Maine, 5 locations in Oklahoma, 4 locations in Oregon, 3 locations in Washington, 2 locations in Nevada, 1 location in Arizona, 1 location in Rhode Island,1 location in Florida, and 1 location in Massachusetts.
GrowGen also operates an online superstore for cultivators at growgeneration.com and B2B e-commerce platform, agron.io. GrowGen carries and sells thousands of products, including organic nutrients and soils, advanced lighting technology and state of the art hydroponic equipment to be used indoors and outdoors by commercial and home growers.
About Groundwork BioAg:
Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.dynomyco.com, or follow: Facebook, Twitter, Instagram, LinkedIn, YouTube.
<<<
>>> Israel Aerospace Industries Ltd. develops and produces military and commercial aerospace and defense systems.
https://www.crunchbase.com/organization/israel-aerospace-industries?utm_source=yahoo&utm_medium=referral&utm_content=profile_cta&utm_campaign=yahoo_finance
The company provides space systems including communication and observation satellites, launchers, ground stations and systems, and subsystems and components; and unmanned air systems comprising of electro-optical payloads, inertial systems, maritime solutions, ground control and airborne systems, and data terminals. The company also offers defense systems; military aircraft and helicopters maintenance and upgrade services including services for special mission aircraft, aero structures and wiring, training solutions and systems, operational support products and services, airborne systems, tactical mid-air collision avoidance systems, defense self-protection communications, A/C and engine parts, telemetry and airborne instrumentation equipment, toolkits, and helicopter military seats.
In addition, the company provides naval systems such as surveillance systems, patrol and attack crafts, training and simulation products, ship combat suites, combat management systems, naval attack missiles, naval LAHAT and Barak systems, sea-to-sea missiles, weapon systems modernization and integration services, radar systems, and skimmers. The company also offers maintenance, repair, overhaul, and conversion services for civil aircrafts; integrated intelligence systems, air command control communication systems, radars, and defense and self-protection products; land systems comprising of land-based Barak systems, armored dozers, airborne systems for aerostats, mine blast resistant seats, land navigation systems, precision strike systems and guided munitions, loitering weapons, ground vehicles, field porters, and ground SIGINT systems.
Israel Aerospace Industries also offers cyber defense, maritime, border protection, defense surveillance systems, and crisis and emergency management systems, as well as business jets and aero assemblies.
Israel Aerospace Industries was founded in 1953 and is based in Lod, Israel.
<<<
>>> Israel debuts battlefield robot to support, protect troops
By Mike Glenn
The Washington Times
September 13, 2021
https://www.washingtontimes.com/news/2021/sep/13/israel-debuts-battlefield-robot-support-protect-tr/
An Israeli defense contractor on Monday rolled out a remote-controlled armed robot that its maker says can keep human troops out of harm’s way. The Rex MK II is just the latest unmanned combat system that is changing the face of tomorrow’s battlefield.
Developed by the state-owned Israel Aerospace Industries, the Rex MK II can be adapted for a variety of missions, ranging from gathering intelligence to logistics support, with the capacity to carry a load of up to 1.3 tons. Armed with an arsenal that includes .50 caliber and 7.62 mm machine guns, it can also help conduct attacks.
“The multi-mission Rex MK II is intended to support infantry ground troops in various stages of fighting,” company officials said in a statement. “This includes providing logistical assistance to troops by carrying munition supplies, critical medical equipment, water and food, as well as evacuating injured personnel on stretchers.”
The robot also can be used to gather intelligence through a system that incorporates electro-optical sensors and radar. The Rex MK II is not fully autonomous — it requires a human controller — but it can drive itself to a set location on its own and use its optical sensors to bypass obstacles in its path.
Some critics have warned that even semi-autonomous systems like the Rex MK II are another step closer to battlefield robots that can attack targets on their own. Human Rights Watch launched the “Campaign to Stop Killer Robots” to ensure human control over the use of force.
Israel uses a smaller military robot called a Jaguar to patrol its volatile southern border with Gaza, and has developed several other unmanned systems for battlefield use, including the RobARC used to uncover and destroy explosive devices, and the RobDozen, an unmanned bulldozer that can carry out complex engineering tasks in danger zones.
“The need to support ground forces in the field to carry out various missions while minimizing threats to soldiers’ lives is at the heart of our values here,” Zvika Yarom, general manager of IAI’s land division, said in a statement. “We are experiencing a rise in demand from clients for unmanned land platforms.”
<<<
$PFE Israel finds COVID-19 vaccine booster significantly lowers infection risk
https://www.reuters.com/world/middle-east/israel-finds-covid-19-vaccine-booster-significantly-lowers-infection-risk-2021-08-22/
>>> Nano-X Imaging Drops After FDA Seeks More Data on New X-Ray System
Nano-X Imaging fell after the FDA requested additional information concerning the company's application for its portable X-ray system.
The Street
8-19-21
by VIDHI CHOUDHARY
https://www.thestreet.com/investing/nano-x-drops-after-fda-seeks-more-data-on-portable-x-ray-device?puc=yahoo&cm_ven=YAHOO
Shares of Nano-X Imaging (NNOX) - Get Nano X Imaging LTD Report dropped Thursday after the U.S. Food and Drug Administration sought additional information on the Israeli medical-tech company's portable X-ray system.
Shares of the Neve Ilan, Israel, company at last check fell 8.4% to $21.70.
Stocks Fail to Hold Momentum as Fed Taper Talk Too Much for Wall Street
"The submission file is placed on hold pending a complete response to the FDA's list of deficiencies," the company said in a regulatory filing made to the Securities and Exchange Commission.
Nano-X Imaging plans to respond by the due date, which is 180 days from Aug. 12.
The company also said that it expected to continue to optimize and develop further features of the system, called Nanox.ARC.
Nano-X also said in the filing that it's considering submitting an application for the latest model of the multisource Nano.ARC system.
That first version has FDA clearance, and the company said the new model would benefit from the FDA's feedback.
<<<
>>> Else Nutrition Signs Distribution Agreement with Walmart.com
Else Nutrition Holdings Inc.
August 12, 2021
https://finance.yahoo.com/news/else-nutrition-signs-distribution-agreement-110000268.html
Else Toddler Nutrition to be available at Nation’s Largest Grocery Retailer’s online store by Q4 2021
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, announces that it has signed an online distribution agreement with Walmart.com and will be expanding into Walmart’s E-commerce (Walmart.com) marketplace by Q4, 2021 with its Plant-Based Complete Nutrition products for Toddlers.
“Entering Walmart.com is a highly significant milestone for the Company,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “The sheer size of Walmart.com will allow us to reach thousands of new families and enable us to scale significantly over the next 3 years,” she added.
According to eMarketer, Walmart’s U.S. e-commerce sales prior to the pandemic were $30 billion and are projected to hit over $64 billion by the end of 2021.
Walmart.com’s traffic was much higher the past year than pre-pandemic levels. Online shopping, particularly in the grocery and FMCG segment (Fast Moving Consumer Goods), has undergone a surge in popularity due to the pandemic. Walmart was the largest United States grocery retailer in 2019 with 65 percent of Walmart's US$510.329 billion sales coming from U.S. operations.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
<<<
>>> Magic Software Enterprises Ltd. (MGIC) provides proprietary application development, business process integration, vertical software solutions, and information technologies (IT) outsourcing software services in Israel and internationally. The company's Software Services segment develops, markets, sells, and supports application platform, software applications, and business and process integration solutions and related services. Its IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, and supplemental outsourcing services. The company offers proprietary application platforms, such as Magic xpa for developing and deploying business applications; AppBuilder for building, deploying, and maintaining high-end and mainframe-grade business applications; Magic xpi for application integration; Magic xpc, a hybrid integration platform as a service; Magic SmartUX, a mobile development application platform; and FactoryEye for virtualization of production data. It also provides vertical software solutions comprising Clicks, a software solution for healthcare providers; Leap, a software solution for business support systems; Hermes Solution, a packaged software solution for managing air cargo ground handling; HR Pulse, a customized single-tenant software as a service tool; and MBS Solution, a proprietary system for managing TV broadcast management. In addition, the company provides software maintenance, support, training, and consulting services. It serves oil and gas, telecommunications, financial, healthcare, and industrial sectors; and public institutions and international agencies. The company was formerly known as Mashov Software Export (1983) Ltd. and changed its name to Magic Software Enterprises Ltd. in 1991. Magic Software Enterprises Ltd. was incorporated in 1983 and is headquartered in Or Yehuda, Israel.
<<<
>>> Israeli Firm’s Spyware Found on Phones Worldwide, Post Says
Bloomberg
By Yueqi Yang
July 18, 2021
https://www.bloomberg.com/news/articles/2021-07-18/israeli-firm-s-spyware-found-on-phones-worldwide-post-says?srnd=premium
Investigation shows phones of journalists, activists targeted
NSO Group denies findings, calls them exaggerated and baseless
Israeli company NSO Group Ltd.’s Pegasus spyware was used in attempted and successful hacks of 37 smartphones belonging to journalists, activists and business executives worldwide, according to an investigation by The Washington Post and its media partners.
Among the findings is that the spyware was used to target the smartphones of both the wife and the fiancee of murdered Saudi columnist Jamal Khashoggi. Their phone numbers appeared on a list of more than 50,000 numbers, which the consortium said were possible targets for surveillance by governments using Pegasus.
Also on the list are phone numbers of overseas journalists for news organizations, including CNN, the Associated Press, Voice of America, the New York Times, the Wall Street Journal, Bloomberg News, Le Monde in France, the Financial Times and Al Jazeera in Qatar.
“The sort of surveillance being reported is an appalling violation of press freedoms and we strongly condemn it,” said a Bloomberg News spokesperson.
The media consortium, led by the Paris-based not-for-profit Forbidden Stories, said it was revealing evidence extracted from the phones through digital forensic analysis by Amnesty International’s security lab.
Pegasus, sold to select governments and law enforcement agencies, can hack into mobile phones through a link and secretly record emails, calls and text messages. In some cases, it can activate itself without the victim clicking on the link, the Post said. It’s unknown how many of the phones on the list were targeted or surveilled, the Post said.
In response to the consortium, NSO denied that its technology was used against Khashoggi and said the investigation contained flawed assumptions and factual errors.
Last month, NSO Group published its first annual “Transparency and Responsibility Report,” which said its products have been used by states to thwart major terrorist attacks and dismantle drug trafficking rings.
More findings from the investigation will be rolled out in the next three days, the Post said.
<<<
ElectReon - >>> Israeli Startup Sees Electricity Paving Road to the Future
ElectReon uses induction technology to recharge batteries on the go
Bloomberg Green
July 6, 2021
https://www.bloomberg.com/news/articles/2021-07-06/israel-s-electreon-charges-electric-car-batteries-on-the-go?srnd=premium
Oren Ezer insists that the road to the electric-vehicle future will be paved with ... well ... asphalt, just like today’s highways. But beneath the surface, Ezer says, will be conductive coils that can wirelessly charge battery-powered cars, buses, and trucks, offering a fix for the biggest hurdle in the emerging EV industry: range anxiety. ElectReon Wireless Ltd., the company Ezer co-founded in 2013, has lined 6 kilometers of roads in Israel and Sweden to prove the viability of the idea, and it’s working on similar projects in Germany and Italy.
ElectReon uses 1.2-meter-long coils buried fist deep in the road to deliver power to vehicles. To test the technology, ElectReon equipped a bus with three receivers under the chassis to pick up the charge on the go, using induction technology similar to plug-free phone-charging mats. The layer of asphalt zeros out the chance of passersby getting electrocuted, Ezer says. “There are no pyrotechnics,” he says while riding the bus on the 2-km stretch of a road in northern Tel Aviv where the technology is installed in 100-meter-long sections spaced about 200 meters apart. “You get on the road. You get your charge. You keep moving.”
The potential for such systems is huge as electric vehicles accounted for less than 5% of new car sales globally last year—and 2% in the U.S.—in large part because would-be buyers fret about the hassles of refueling. President Joe Biden wants to build 500,000 charging stations across the U.S. by 2030 at a cost of $15 billion. Germany, which is testing electric highways around Frankfurt, Hamburg, and Stuttgart, expects as many as 10 million electric vehicles on its roads by the end of the decade, about 20 times the current figure. Sweden, aiming for zero net emissions by 2045, plans to build 2,400 kilometers (1,491 miles) of electric roads by 2037.
ElectReon is facing some formidable rivals. Germany’s Siemens AG has developed catenaries—the spring-loaded systems atop many trains—that attach to wires strung above roads to give trucks a boost. French transport giant Alstom SA is among multiple companies that are working on street-level rails that deliver power through a sliding contact below the vehicle, which proponents say is safe because the systems are activated in short bursts or only when cars drive over them. But when Sweden wanted to test the idea on a 2.5-mile shuttle bus route to the airport on Gotland Island two years ago, it chose ElectReon, largely because any unsightly equipment is hidden beneath the pavement.
The Swedish Transport Administration says ElectReon’s system in Gotland costs about €1 million ($1.2 million) per kilometer, slightly more than half the price of a catenary network. But ElectReon’s coils deliver about a quarter of the electricity—energy travels more efficiently when the power source is in direct contact with the battery—so the company would require more infrastructure to achieve the same level of charging. The ElectReon system “is easy to deploy and has almost no visible parts and hopefully also low maintenance costs,” says Jan Pettersson, director of strategic development at the Swedish Transport Administration. But reaching Sweden’s climate goals will require “a whole palette of solutions,” including fast-charging stations or heavy trucks powered by hydrogen fuel cells, which promise much longer ranges, he says.
ElectReon has increased the amount of energy it can transfer, to 25 kilowatt hours per receiver—almost 10 times what it was a few years ago—and it aims to hit 45 kWh by next year. At the current rate, the average city bus could run a full day on two hours of charging, says Ezer. It’s testing the technology with Renault on the compact electric Zoe and on buses and trucks with Volkswagen, Jeep, and China’s Higer. ElectReon is nearing deals with two other car manufacturers that it aims to conclude by December, and it expects to begin highway projects in Germany and Italy in the coming months. “There’s an almost limitless market,” Ezer says.
Skeptics say the technology risks being rendered obsolete by improvements in battery performance. Volvo Group AG, which recently teamed up with Daimler Truck AG on hydrogen-fuel-cell trucks after passing on an electric roads partnership with Alstom, says such systems would cost taxpayers 10 times as much as fixed charging stations. The “costs, benefits and uncertainties clearly speak against a large-scale electric road investment,” says Claes Eliasson, a senior vice president at Volvo.
Ezer maintains that the viability of his system isn’t threatened by better batteries. ElectReon’s on-the-go charging would allow vehicles to have much smaller power reservoirs, which means an electric bus using the technology could cost significantly less than one with a full-size battery. Similar math applies to private cars, according to Martin Gustavsson, project coordinator at Swedish Electric Transport Laboratory. “It’s become more and more apparent that with electric roads,” Gustavsson says, “cars could drive very long distances without large, heavy, and expensive batteries.”
<<<
Nano Dimension Ltd - >>> 10 Best Cheap Tech Stocks to Buy According to Cathie Wood
Insider Monkey
May 26, 2021
https://finance.yahoo.com/news/10-best-cheap-tech-stocks-145316098.html
Number of Hedge Fund Holders: 11
Nano Dimension Ltd. (NASDAQ: NNDM) is an Israel-based 3D printing company founded in 2012. It is placed ninth on our list of 10 best cheap tech stocks to buy according to Cathie Wood. The company stock has returned more than 150% to investors over the course of the past twelve months. ARK Investment holds close to 13 million shares in the company worth over $111 million. This represents 0.22% of their portfolio. Nano Dimension primarily focuses on research and development related to 3D printed electronics.
In earnings results for the first three months of 2021, posted on May 20, Nano Dimension Ltd. (NASDAQ: NNDM) reported earnings per share of -$0.05 and a revenue of $0.8 million. The revenue was up over 15% compared to the same period last year.
Out of the hedge funds being tracked by Insider Monkey, New York-based investment firm Renaissance Technologies is a leading shareholder in Nano Dimension Ltd. (NASDAQ: NNDM) with 6.6 million shares worth more than $57 million.
<<<
>>> Israel Set To Swear in New Government, Ending Netanyahu's Rule
Time Magazine
BY JOSEPH KRAUSS
JUNE 13, 2021
https://time.com/6073226/israel-new-government-netanyahu/
(JERUSALEM) — Israel is set to swear in a new government on Sunday that will send Prime Minister Benjamin Netanyahu into the opposition after a record 12 years in office and a political crisis that sparked four elections in two years.
Naftali Bennett, the head of a small ultranationalist party, will take over as prime minister. But if he wants to keep the job, he will have to maintain an unwieldy coalition of parties from the political right, left and center.
The eight parties, including a small Arab faction that is making history by sitting in the ruling coalition, are united in their opposition to Netanyahu and new elections but agree on little else. They are likely to pursue a modest agenda that seeks to reduce tensions with the Palestinians and maintain good relations with the U.S. without launching any major initiatives.
Netanyahu, who is on trial for corruption, remains the head of the largest party in parliament and is expected to vigorously oppose the new government. If just one faction bolts, it could lose its majority and would be at risk of collapse, giving him an opening to return to power.
The country’s deep divisions were on vivid display as Bennett addressed parliament ahead of the vote. He was repeatedly interrupted and loudly heckled by supporters of Netanyahu, several of whom were escorted out of the chamber.
Bennett’s speech mostly dwelled on domestic issues, but he expressed opposition to U.S. efforts to revive Iran’s nuclear deal with world powers.
“Israel will not allow Iran to arm itself with nuclear weapons,” Bennett said, vowing to maintain Netanyahu’s confrontational policy. “Israel will not be a party to the agreement and will continue to preserve full freedom of action.”
Bennett nevertheless thanked President Joe Biden and the U.S. for its decades of support for Israel.
Netanyahu, speaking after him, vowed to return to power. He predicted the incoming government would be weak on Iran and give in to U.S. demands to make concessions to the Palestinians.
“If it is destined for us to be in the opposition, we will do it with our backs straight until we topple this dangerous government and return to lead the country in our way,” he said.
Yohanan Plesner, president of the Israel Democracy Institute, a nonpartisan think tank, said the new government will likely be more stable than it appears.
“Even though it has a very narrow majority, it will be very difficult to topple and replace because the opposition is not cohesive,” he said. Each party in the coalition will want to prove that it can deliver, and for that they need “time and achievements.”
Still, Netanyahu “will continue to cast a shadow,” Plesner said. He expects the incoming opposition leader to exploit events and propose legislation that right-wing coalition members would like to support but can’t — all in order to embarrass and undermine them.
The new government is meanwhile promising a return to normalcy after a tumultuous two years that saw four elections, an 11-day Gaza war last month and a coronavirus outbreak that devastated the economy before it was largely brought under control by a successful vaccination campaign.
The driving force behind the coalition is Yair Lapid, a political centrist who will become prime minister in two years, if the government lasts that long.
He called off a planned speech to parliament, instead saying he was ashamed that his 86-year-old mother had to witness the raucous behavior of his opponents. In a brief speech, he asked for “forgiveness from my mother.”
“I wanted her to be proud of the democratic process in Israel. Instead she, along with every citizen of Israel, is ashamed of you and remembers clearly why it’s time to replace you,” he said.
The new government is expected to win a narrow majority in the 120-member assembly, after which it will be sworn in. The government plans to hold its first official meeting later this evening.
It’s unclear if Netanyahu will move out of the official residence. He has lashed out at the new government in apocalyptic terms and accused Bennett of defrauding voters by running as a right-wing stalwart and then partnering with the left.
Netanyahu’s supporters have held angry protests outside the homes of rival lawmakers, who say they have received death threats naming their family members. Israel’s Shin Bet internal security service issued a rare public warning about the incitement earlier this month, saying it could lead to violence.
Netanyahu has condemned the incitement while noting that he has also been a target.
His place in Israeli history is secure, having served as prime minister for a total of 15 years — more than any other, including the country’s founder, David Ben-Gurion.
Netanyahu began his long rule by defying the Obama administration, refusing to freeze settlement construction as it tried unsuccessfully to revive the peace process. Relations with Israel’s closest ally grew even rockier when Netanyahu vigorously campaigned against President Barack Obama’s emerging nuclear deal with Iran, even denouncing it in an address to the U.S. Congress.
But he suffered few if any consequences from those clashes and was richly rewarded by the Trump administration, which recognized contested Jerusalem as Israel’s capital, helped broker normalization agreements with four Arab states and withdrew the U.S. from the Iran deal.
Netanyahu has portrayed himself as a world-class statesman, boasting of his close ties with Trump and Russian President Vladimir Putin. He has also cultivated ties with Arab and African countries that long shunned Israel over its policies toward the Palestinians.
But he has gotten a far chillier reception from the Biden administration and is widely seen as having undermined the long tradition of bipartisan support for Israel in the United States.
His reputation as a political magician has also faded at home, where he has become a deeply polarizing figure. Critics say he has long pursued a divide-and-conquer strategy that aggravated rifts in Israeli society between Jews and Arabs and between his close ultra-Orthodox allies and secular Jews.
In November 2019, he was indicted for fraud, breach of trust and accepting bribes. He refused calls to step down, instead lashing out at the media, judiciary and law enforcement, going so far as to accuse his political opponents of orchestrating an attempted coup. Last year, protesters began holding weekly rallies across the country calling on him to resign.
Netanyahu remains popular among the hard-line nationalists who dominate Israeli politics, but he could soon face a leadership challenge from within his own party. A less polarizing Likud leader would stand a good chance of assembling a coalition that is both farther to the right and more stable than the government that is set to be sworn in.
<<<
>>> Varonis Systems, Inc. (VRNS) provides software products and services that allow enterprises to manage, analyze, and secure enterprise data in North America, Europe, the Middle East, Africa, and internationally. Its software enables enterprises to protect data stored on premises and in the cloud, including sensitive files and emails; confidential personal data belonging to customers, and patients and employees' data; financial records; strategic and product plans; and other intellectual property. The company offers DatAdvantage that captures, aggregates, normalizes, and analyzes every data access event for users on Windows and UNIX/Linux servers, storage devices, email systems, and Intranet servers; and DatAlert that profiles users and their behaviors related to systems and data, detects and alerts on deviations that indicate compromise, and provides a Web-based dashboard and investigative interface. It also provides Data Classification Engine that identifies and tags data based on criteria set in various metadata dimensions, and provides business and information technology (IT) personnel with actionable intelligence about data; and DataPrivilege, which provides a self-service Web portal that allows users to request access to data necessary for their business functions, and owners to grant access without IT intervention. In addition, the company offers Data Transport Engine, which provides an execution engine that unifies the manipulation of data and metadata, translating business decisions, and instructions into technical commands, such as data migration or archiving; and DatAnswers that offers search functionality for enterprise data. It sells its products and services through a network of distributors and resellers. The company serves IT, security, and business personnel. Varonis Systems, Inc. was incorporated in 2004 and is headquartered in New York, New York.
<<<
>>> Has Israel just found the cure for Covid?
Experimental Covid drug cures 30 out of 30 moderate to severe cases in Phase I clinical trial at Israeli hospital. Second new drug also shows promise.
Israel 21c
By Abigail Klein Leichman
FEBRUARY 7, 2021
https://www.israel21c.org/has-israel-just-found-the-cure-for-covid/
Even with Israel’s world-leading rollout of Covid-19 vaccinations, drugs to treat Covid patients are in desperate need across the world.
Two such drugs developed in Israel show great promise in clinical trials: EXO-CD24 and Allocetra.
EXO-CD24, an experimental inhaled medication developed at Tel Aviv Sourasky Medical Center, cured all 30 moderate-to-severe cases in a Phase I clinical trial.
Developed over the past six months at the hospital, EXOCD24 stops the “cytokine storm” – where the immune system goes out of control and starts attacking healthy cells – that occurs in the lungs of 5-7% of Covid-19 patients.
“To date, the preparation has been tried with great success on 30 severe patients, in 29 of whom the medical condition improved within two to three days and most of them were discharged home within three to five days. The 30th patient also recovered but after a longer time,” the hospital reports.
“The drug is based on exosomes, [vesicles] that are released from the cell membrane and used for intercellular communication. We enrich the exosomes with 24CD protein. This protein is expressed on the surface of the cell and has a known and important role in regulating the immune system,” explained Dr. Shiran Shapira, director of the laboratory of Prof. Nadir Arber, who has been researching the CD24 protein for over two decades.
“The preparation is given by inhalation, once a day, for only a few minutes, for five days,” Shapira said.
She said the experimental treatment has two unique characteristics. The first is that it inhibits the over-secretion of cytokines. The second is that it is delivered directly to the lungs and therefore has no systemic side effects that injected or oral drugs can cause.
“Even if the vaccines perform their function, and even if no new mutations are produced then still in one way or another the corona will remain with us,” said Arber, director of the medical center’s Integrated Cancer Prevention Center. “To this end, we have developed a unique drug, EXO-CD24.”
Arber added that this advanced preparation “can be produced quickly and efficiently and at a very low cost in every pharmaceutical facility in the country, and in a short time globally.”
Prof. Ronni Gamzu, CEO of the medical center, said, “Prof. Arber’s results for first-phase research were excellent and gave us all confidence in the method he has been researching [here] for many years. I personally assisted him in further obtaining the approvals from the Ministry of Health for further research.”
Allocetra
Meanwhile, Enlivex Therapeutics last week reported positive results from a multi-center Phase II clinical trial of its experimental Covid-19 immunotherapy drug Allocetra in severe and critical Covid-19 patients.
We reported in October that five Covid-19 intensive care patients were discharged from Hadassah University Medical Center in Jerusalem after treatment with Allocetra.
Nine severe and seven critical Covid-19 patients were treated with Allocetra in the Phase II clinical trial. Fourteen of them recovered and were discharged from the hospital after an average of 5.3 days.
The Phase II trial originally was expected to enroll 24 patients but was “completed early in support of anticipated accelerated regulatory filings of the trial’s positive safety and efficacy data,” Enlivex reported.
Altogether, 19 out of 21 Phase II and Phase Ib Allocetra trial patients recovered and were discharged from the hospital after an average of 5.6 days. Most of the patients in both studies had pre-existing risk factors such as male gender, obesity and hypertension.
“The results we have seen from the 12 Covid-19 patients treated to date with Allocetra are exciting,” said Prof. Vernon van Heerden, head of the General Intensive Care Unit at Hadassah and the lead investigator of both clinical trials.
“The Phase II patients who have been discharged from the hospital are currently healthy. We believe that these compelling results have demonstrated the safety and efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex’s product candidate to benefit severe and critical Covid-19 patients as well as others suffering from cytokine storms and organ dysfunctions across various clinical indications.”
Allocetra is based on the research of Enlivex chief scientific and medical officer Dr. Dror Mevorach, head of internal medicine and of one of Hadassah’s coronavirus wards. It works by restoring balance to the immune system.
Mevorach said Allocetra “may have utility as a safe and efficacious treatment … regardless of the specific coronavirus mutation that afflicted the patients, and across different life-threatening, high mortality clinical indications with high unmet medical needs.”
<<<
Nano-X Imaging (NNOX), Nano Dimension (NNDM) -
>>> Have $3,000? Buying These 2 Stocks Would Be the Smartest Move You Ever Made
Both companies are using nanotechnology to revolutionize healthcare and manufacturing. Plus, they have considerable upside.
Motley Fool
by Taylor Carmichael
Jan 31, 2021
https://www.fool.com/investing/2021/01/31/have-3000-buying-these-3-stocks-would-be-the-smart/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
You don't need to invest a lot of money to have amazing returns in the stock market. If you invested $3,000 in Amazon (NASDAQ:AMZN) 20 years ago, you could have bought 300 shares. At a Jan. 29 price of $3,203 per share, your $3,000 investment would now be worth $960,900. To pull off an investment like that, you had to be willing to take risks (Amazon was unprofitable in its early years), practice patience, and let the growth story play out.
Are there any stocks in 2021 with Amazon-sized futures? Yes, there are. A few that come to mind are small companies using nanotechnology to disrupt the healthcare and manufacturing industries. Nano-X (NASDAQ:NNOX) has a device that could make X-rays a lot cheaper and more accesible. And Nano Dimension (NASDAQ:NNDM) uses nanotechnology (and 3-D printing) to revolutionize the way companies manufacture electronic circuit boards. Read more to find out why these stocks might be wonderful for patient, risk-tolerant investors.
1. Smaller is better for Nano-X
Nanotechnology led to the breakthrough.
The problem with high-end X-ray machines like those using magnetic resonance imaging (MRI) or computerized axial tomography (CAT) is that the machines are massive and cost hospitals over $1 million, and in some cases as much as $3 million. These high-end medical X-ray systems have to generate a tremendous amount of heat for the X-ray to happen -- up to 2,000 degrees Celsius (3,600 degrees Fahrenheit). Using micro-electrical-mechanical-systems (MEMS), Nano-X was able to fabricate millions of nanoscale gates on a silicon chip. Each one of these microscopic "nano-spindts" digitally creates and controls the electrons that power an X-ray device.
The result is that we no longer need to generate heat for an X-ray to work. Instead of having to power up to 3,600 degrees Fahrenheit -- and then cool down -- the Nano-X device stays at room temperature. Thus the company was able to build a much smaller, and cheaper, X-ray machine. And yes, the engineers who designed the sleek machine were inspired by Star Trek.
Nano-X says the device -- once it's cleared by the U.S. Food and Drug Administration (FDA) -- will cost about $10,000 to manufacture. But what's exciting the market is not how cheap the device is, or even how popular it might be. What's truly getting investors jazzed is that Nano-X will take a small percentage of the fee every time its X-ray device is used. That's the classic razor-and-blades pricing model that helped make Intuitive Surgical (NASDAQ:ISRG) investors rich. Nano-X can actually give its machine away, because it's making money on the use of the device, not on the original sale.
Will the device work as well as the MRI and CAT scans common in hospitals today? Skeptics abound. The company has no profits (or even revenues) yet. Shorts and other traders have made Nano-X's stock price incredibly volatile. But early investors who took the plunge upon its IPO in August are doing quite well so far.
2. Using Nanotech to transform 3D printing
3D printing has been around for decades. It's now become fairly commonplace in many industries. For instance, SmileDirectClub (NASDAQ:SDC) uses 3D printers to create aligners for your teeth. Nonetheless, this revolution in manufacturing is just beginning. And Nano Dimension might just be the most important company in 3D manufacturing today.
Nano Dimension uses nanoparticles to transform the inks used in 3D printing. Its Dragonfly device allows designers and engineers to print functional circuit boards and other electronic devices.
This is huge, for any number of reasons. Research and design labs can keep their intellectual property secret, because they can manufacture in-house cheaply, quickly, and easily. But 3D printing has an added benefit -- you can print devices with parts that are so tiny, they were impossible to manufacture before. As the company puts it on its website, designers can "pack more functionality in smaller footprints."
Nano Dimension has customers in aerospace and defense industries, but also in healthcare. Medical device companies can now 3D print noninvasive sensors and micro devices.
The most enticing thing about Nano Dimension for investors is its business model. The company has sold only 60 devices so far. But, as with Nano-X and Intuitive Surgical, the real money will be made in service revenues. Nano Dimension will make its money by supplying the miraculous inks that allow these systems to work. The more companies use its device to print circuit boards, the more money Nano Dimension will make.
This recurring revenue model is a wonderful business to invest in. While these small and unprofitable companies are certainly risky -- and highly volatile in the short term -- patient investors with a long-term outlook can easily make a fortune if either company pulls it off. That's the key to investing in early-stage companies -- don't put all your eggs in one basket. And hold on to your shares to see how it all unfolds. Patient investors who understand the risks might just see some amazing returns down the road.
<<<
>>> Israeli Startup Otonomo Nearing Merger With Software SPAC
Bloomberg
By Gillian Tan, David Welch, and Edward Ludlow
January 29, 2021
https://www.bloomberg.com/news/articles/2021-01-29/israeli-startup-otonomo-said-nearing-merger-with-software-spac?srnd=premium
Platform is fueled by data from more than 22 million vehicles
Otonomo’s earlier investors include Bessemer, Avis, Maniv
Otonomo, an Israeli startup that operates a data platform linked to millions of connected cars, is in talks to go public through a merger with Software Acquisition Group Inc. II, according to a person with knowledge of the matter.
The special purpose acquisition company is in talks to raise new equity to support a transaction that could be announced as soon as next week, said the person, who requested anonymity because the information isn’t public. The deal size couldn’t immediately be learned and it’s possible that, as with any deal that isn’t finalized, talks could collapse.
A representative for Software Acquisition Group declined to comment. Representatives for Otonomo didn’t immediately respond to requests for comment.
The SPAC’s shares rose 18% in after-hours trading on Friday.
Otonomo, led by Chief Executive Officer and founder Ben Volkow, takes over 4 billion data points per day from more than 22 million connected vehicles, according to its website.
The data is used for emergency services, mapping, parking and predictive maintenance, and partners include BMW AG, Daimler AG, Mitsubishi Motors Corp. and Mercedes-Benz.
The company last year raised fresh capital from investors including SK Holdings Co., Avis Budget Group, Maniv Mobility, Alliance Ventures and Bessemer Venture Partners. It was valued at about $465 million after that funding round, PitchBook data shows.
Software Acquisition Group, led by CEO Jonathan Huberman, raised $172.5 million in a September initial public offering and said at the time that it intends to focus its search on software companies.
Huberman’s first SPAC in October merged with CuriosityStream Inc., a media company that specializes in documentaries, among other features.
<<<
BioCatch (private) - >>> The Leader in AI-Driven Behavioral Biometrics
https://www.biocatch.com/company/our-story
BioCatch was founded in 2011 by experts in neural science, artificial intelligence (AI), machine learning and cyberterrorism. The newly-founded company had a significant mission: to address next-generation digital identity challenges by focusing on online user behavior rather than static authentication measures, like passwords or endpoint security. They discovered an untapped goldmine.
Powerful behavioral insights — gleaned from the analysis of more than 2,000 physical and cognitive behavioral parameters — were able to support different use cases across the digital identity lifecycle. The technology enabled the holy grail of the modern digital era — seamless and secure online experiences. Behavioral biometrics, a technology used to identify people based on their behavioral parameters, was born.
BioCatch founder Avi Turgeman began pursuing a theory that people interact with machines in unique, measurable ways while serving in military intelligence. Drawing on years of experience exploring white-hat hacking, system vulnerability management and cyberterrorist operations, Turgeman turned his attention to online fraudsters and their identifiable signatures, co-founding BioCatch with Benny Rosenbaum.
In developing their AI-driven platform to passively identify both human and non-human behaviors online, BioCatch upended the paradigm of having to choose between security and convenience. Today, the company continues its commitment to innovation through an unparalleled IP portfolio of more than 60 granted or pending patents.
The BioCatch platform is deployed by major banks and other global enterprises to help manage their digital identity challenges. The technology prevents new account fraud, authenticates online users, prevents account takeover fraud and detects vishing scams, generating impressive returns on investment that come from catching more fraud as well as reducing false positives and unnecessary escalations.
BioCatch has been recognized for its industry leadership and cutting-edge approach to behavioral biometrics and digital identity in the CB Insights AI 100, One World Identity Leading Innovators in Identity, Deloitte Technology Fast 500, Florin Awards for Best Innovation in Securing Transactions and more.
<<<
>>> SolarEdge Technologies (SEDG) makes power optimizers and inverters that help lower the cost of energy produced by solar panels. Sales of the company's products have been growing at a brisk pace, which will likely continue given the anticipated accelerating growth rate for solar. With costs of panels and battery storage coming down, industry watchers forecast that solar installations will quicken from an average of 10 GW per year in the 2019-2022 timeframe to 18-20 GW per year in between 2023 and 2030. With a cash-rich balance sheet, SolarEdge has the financial flexibility to continue expanding so that it can stay ahead of the technological curve and capture a sizable portion of this growth. <<<
https://www.fool.com/investing/2020/12/06/got-5000-here-are-5-energy-stocks-to-buy-and-hold/
>>> Israeli scientist uses microbubbles to explode cancer cells
Low-frequency ultrasound bursts microscopic bubbles injected into tumors; explosion kills the majority of the surrounding cancer cells.
By Naama Barak
AUGUST 9, 2020
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157554495
An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s.
The groundbreaking technique, developed by Tel Aviv University’s Tali Ilovitsh during her post-doctorate period at Stanford University, uses low-frequency ultrasound to burst microscopic tumor-targeted bubbles. Her research was recently published in the journal Proceedings of the National Academy of Sciences.
“Microbubbles are microscopic bubbles filled with gas, with a diameter as small as one-tenth of a blood vessel. At certain frequencies and pressures, soundwaves cause microbubbles to act like balloons: microbubbles expand and shrink periodically, and thus allow an increased transfer of substances from the blood vessel to the surrounding tissue,” Ilovitsh explained.
“We discovered that using lower frequencies than those applied before causes microbubbles to expand drastically until they explode. We understood that this discovery can be used as a tumor-treatment platform and started injecting microbubbles into tumors directly.”
Two-pronged approach
The research team injected microbubbles into tumors in engineered mice. The microbubbles were tumor-targeted, meaning that they attached to the tumor cells’ membranes at the moment of explosion.
“Around 80 percent of tumor cells were killed in the explosion, which is already positive,” Ilovitsh says. “The targeted treatment, which is safe and cheap, managed to destroy most of the tumor.”
And yet, to prevent the cancer from spreading, the researchers needed to destroy every cancer cell.
“That is why we injected an immunotherapeutic gene alongside the microbubbles, which acts as a Trojan horse and signals the immune system to attack the cell,” Ilovitsh said.
This gene that alerts the immune system to attack normally cannot enter cancer cells. Introduced by the exploding microbubbles, it managed to enter the cells that were not killed by the explosion and signal to the body that they were cancerous.
“The cancer cells were hit by the explosion, and through the holes that were created the gene we inserted into the microbubbles was transferred inside. Cancer cells that managed to heal and close themselves absorbed the gene that makes them produce a substance alerting the immune system to attack the cell,” Ilovitsh explained.
“In fact, our model mice had tumors on both sides of the body. Despite the fact that we injected microbubbles only to the tumor on one side, the immune system attacked the other side as well,” she relates.
Ilovitsh intends to use the technology that she developed as a noninvasive treatment for brain-damaging diseases such as Alzheimer’s, Parkinson’s and brain tumors.
“The blood-brain barrier does not allow medications to pass through, but microbubbles can expand and enable a temporary opening of the barrier, thus letting the treatment reach its target without requiring an operation,” she said.
https://www.israel21c.org/israeli-scientist-uses-microbubbles-to-explode-cancer-cells/
<<<
Ormat - >>> Worried About Another Coronavirus Sell-Off? Buy These 3 Safe Stocks
The pandemic is back in the headlines. Here's how to protect your portfolio.
MarketWatch
John Bromels, Scott Levine, And Lee Samaha
Oct 11, 2020
https://www.fool.com/investing/2020/10/11/worried-about-another-coronavirus-sell-off-buy-the/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Last week ended with the concerning news that President Donald Trump had tested positive for COVID-19. This week began with the grim news that the U.S. had hit its highest daily coronavirus infection rate in two months.
As case numbers across the country continue to rise, investors are smart to be concerned. For those who are worried about how a second coronavirus sell-off might impact their savings, we asked three of our Motley Fool contributors which safe stocks they'd recommend. They came back with Hormel Foods (NYSE:HRL), Brookfield Infrastructure (NYSE:BIP) (NYSE:BIPC), and Ormat Technologies (NYSE:ORA). Here's why.
A conservatively run food company
Lee Samaha (Hormel Foods): This food company is definitely not your average publicly listed corporation. In fact, it appears to be run more like a private company. The Hormel Foundation -- a nonprofit organization set up by Hormel Foods founder George Hormel and his son -- owns 48% of the stock, with institutional shareholders holding 43%. The aims of the foundation are to preserve the company's independence, support the local community, and provide for the welfare of the heirs.
That means the consumer-staples company tends to be conservatively run, with very little debt. And it has a progressive dividend policy: Hormel is a Dividend Aristocrat, having raised its dividend for 54 consecutive years. However, the "safe stock" aspect to its attractiveness doesn't stop at the way the company is run, because Hormel's end markets are relatively stable too.
Slightly over half of its sales go to the U.S. retail market, with 31% to the U.S. food-service market, 10% to U.S. delis, and 7% to the international market. It's a good mix and has given the company resiliency during the COVID-19 crisis. For example, in Hormel's fiscal third quarter, strong growth in retail sales more than offset declines in its food-service sales (as restaurants were forced to close because of COVID-19), leading to 2.2% organic sales growth.
Thinking longer-term, Hormel is hoping its food-service sales will improve as the economy opens up again. In addition, management has made significant acquisitions and capital investments in recent years in order to boost growth. Meanwhile, the long-term case for the stock as a play on demand for protein remains: Pork products (including SPAM, Hormel brand, and Black Label) contribute 50%-55% of sales; turkey (Jennie-O) 18%-22%; non-meat (Skippy) 16%-18%; beef 8%-10%; and chicken and other products 2%-4%.
All told, Hormel is a useful stock for risk-averse investors looking for a dividend yield of nearly 2%.
Infrastructure: The gift that keeps on giving
John Bromels (Brookfield Infrastructure): Generally speaking, the more essential a business is, the "safer" its stock is likely to be. Hormel, above, was a good example: Regardless of what the stock market or the economy are doing, people have to eat. People also have to heat their homes in the winter, keep the lights on, and -- especially during a quarantine -- stay connected with the outside world. And Brookfield Infrastructure helps people around the globe do just that.
Brookfield Infrastructure is part of the Brookfield Asset Management (NYSE:BAM) family, and focuses on four areas: utilities, energy, data infrastructure, and transportation. It's no surprise that the first three of those four areas have not only managed to perform well during the pandemic, they have actually outperformed. The funds from operations (FFO) generated by those three businesses in the first half of 2020 were 8.3% higher than in the first half of 2019.
As you can probably guess, the company's transportation segment -- which owns toll roads, ports, and rail lines -- didn't do so well, as global travel ground to a halt during the height of the pandemic. Management expects this side of the business to recover in 2021. Investors can hop along for the ride by buying the company's shares of stock, with the ticker symbol BIPC, or units of its master limited partnership (MLP), with the BIP ticker. Either one will not only add some safety to your portfolio, but also provide a healthy yield of about 4.9%.
Sleep soundly with this low-risk energy stock
Scott Levine (Ormat Technologies): As global coronavirus cases rise dramatically and leaders implement lockdowns to curb the spread of the pandemic, it's unsurprising that investors are having flashbacks to the volatility which rocked the market last spring. Likewise, the interest in conservative stocks is equally understandable, as investors look to fortify their portfolios against future market turmoil.
For those who find themselves in this situation -- on the lookout for safer stocks -- Ormat Technologies is a name that's well worth considering. A leading global provider of geothermal solutions, Ormat has clear foresight into its future finances, as it often signs long-term power purchase agreements with customers.
In addition to geothermal energy, Ormat is also committed to expanding into the energy-storage market. Last April, for example, Ormat commenced operation of a 10-megawatt (MW) storage facility, Rabbit Hill, in Texas. More recently, in July, Ormat announced the acquisition of its first battery-energy storage facility, Pomona, in California.
While the company's past performance doesn't guarantee future performance, it's worth noting that over the past five years Ormat has provided investors with a total return of 97%, outpacing the 72% gain in the S&P 500.
In terms of its financials, Ormat has succeeded in steadily growing revenue over the past five years -- a period during which it has also increased EBITDA (earnings before interest, taxes, depreciation, and amortization) and operational cash flow:
Like many businesses, Ormat expects the impact of COVID-19 to adversely affect its top line this year. While its 2020 revenue forecast of approximately $718 million (which would be a year-over-year decline of about 4%) may give some investors pause, it's hardly an indication that the company is in peril. In fact, on Ormat's recent Q2 2020 earnings conference call, CEO Doron Blachar stated that the company is "on track to meet [its] 2022 megawatt growth goals" and it's "laying the foundation to enable us to continue our growth path in 2023 and beyond."
Besides its steady revenue and cash-flow generation, the company's circumspect approach to the dividend should appeal to cautious investors. While the modest forward dividend yield of 0.64% may not be much to write home about, the stock's average annual payout ratio over the past five years -- 19.3% -- suggests that management isn't willing to jeopardize the company's financial health in order to attract dividend investors.
<<<
>>> Gamida Cell (GMDA) Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting
September 10, 2020
https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cell-presents-analysis-observational-data
— Study shows younger donor age is associated with improved outcomes following bone marrow transplant —
BOSTON--(BUSINESS WIRE)--Sep. 10, 2020-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced data from an observational study demonstrating that younger donor age is associated with more rapid time to neutrophil engraftment and increased overall survival in patients who received hematopoietic stem cell transplant (HSCT, or bone marrow transplant) for the treatment of hematological malignancies. These data are being presented at the Cord Blood Connect Meeting, which is taking place virtually today and on September 17.
The study is the result of a research agreement between Gamida Cell and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) designed to collect and analyze health outcomes data in patients with hematologic malignancies who receive a hematopoietic stem cell transplant or cellular therapy infusion, including bone marrow transplant graft from various donor sources. The study evaluated clinical outcomes for 660 patients in the CIBMTR registry who underwent a bone marrow transplant with a matched unrelated, mismatched unrelated or haploidentical graft source contemporaneous to the Phase 3 study of omidubicel, Gamida Cell’s investigational advanced cell therapy in development as a treatment option for patients in need of a bone marrow transplant. Key clinical outcomes, including time to neutrophil engraftment and overall survival, were improved for patients with donors under the age of 30.
“As new graft options evolve for bone marrow transplant, and we as a field learn more about the long-term patient outcomes of these graft options, the selection algorithms that are used to match patients with donors must also evolve to take into account the most current clinical data,” said Ronit Simantov, M.D., chief medical officer at Gamida Cell. “These data indicate that donor age is a factor in clinical outcomes and that donor age should be considered when matching patients with a graft source.”
In May, Gamida Cell reported that its Phase 3 study of omidubicel achieved its primary endpoint, demonstrating a highly statistically significant reduction (p < 0.001) in time to neutrophil engraftment, a key milestone in recovery from a bone marrow transplant. Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Gamida Cell expects to begin submitting the biologics license application for omidubicel to the FDA on a rolling basis in the fourth quarter of 2020.
“This analysis reinforces the importance of considering donor age when selecting a bone marrow graft source for patients, as donors aged 30 or younger resulted in improved overall survival,” said Julian Adams, Ph.D., chief executive officer at Gamida Cell. “As we look toward our anticipated regulatory submission of omidubicel to the FDA and potential approval, given that omidubicel is derived from cord blood, we believe these findings could potentially have future implications for considering omidubicel for any patient who does not have an available related or unrelated donor of suitable age.”
More Details About the Study
This observational study utilizes data from the CIBMTR® registry to analyze long-term safety and efficacy data for patients with hematologic malignancies who underwent a bone marrow transplant with a matched unrelated, mismatched unrelated or haploidentical graft source. The criteria for inclusion of patients and the outcomes evaluated in the analyses were consistent with those in the Phase 3 study of omidubicel. The median donor age was 30 (range 2-74) years.
Statistical analyses, performed by Gamida Cell, compared important clinical outcomes for patients with donors ≤ 30 years old (n=334) to patients with donors > 30 years of age (n=326). Patient demographics were well-balanced across the two donor age groups. The study demonstrated that neutrophil recovery was more rapid in patients with donors ≤ 30 years old (p = 0.013). Additionally, patients with donors ≤ 30 years of age showed improved overall survival at one year (p = 0.016).
About Omidubicel
Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). In both Phase 1/2 and Phase 3 clinical studies (NCT01816230 and NCT02730299), omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated.1,2 Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit www.clinicaltrials.gov.
Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.
About the CIBMTR
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a network of more than 300 transplant centers, and one of the largest databases worldwide for clinical outcomes of cellular therapy, and a biorepository with tissue samples.
For more information on the CIBMTR, please visit www.cibmtr.org or follow the CIBMTR on Facebook, LinkedIn, or Twitter at @CIBMTR.
About the National Marrow Donor Program/Be The Match
The National Marrow Donor Program® (NMDP)/Be The Match® is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The NMDP/Be The Match manages the world’s largest registry of potential blood stem cell donors and cord blood units, connects patients to their donor match for a life-saving marrow or umbilical cord blood transplant and educates health care professionals and patients. In 2016, the NMDP/Be The Match established Be The Match BioTherapies® to accelerate patient access to life-saving therapies, by providing proven services and support to companies developing and delivering cell and gene therapies.
Learn more at BeTheMatchClinical.org.
About the Medical College of Wisconsin
With a history dating back to 1893, The Medical College of Wisconsin (MCW) is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,200 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin in 2016. MCW’s School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In FY2016, faculty received more than $184 million in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,500 physicians provide care in virtually every specialty of medicine for more than 525,000 patients annually.
<<<
>>> Ellomay Capital Ltd. (ELLO), together with its subsidiaries, produces and sells renewable and clean energy in Israel, Spain, and the Netherlands. The company owns five photovoltaic (PV) plants comprising four PV plants in Spain with an aggregate installed capacity of approximately 7.9 MWp; and one PV plant in Israel with an installed capacity of approximately 9 MWp. It also operates a dual-fuel power plant with an installed capacity of approximately 860 MWp in the vicinity of Ashkelon, Israel; and engages in the construction of a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel. In addition, the company develops anaerobic digestion plants with a green gas production capacity of approximately 375 Nm3/h in Goor and 475 Nm3/h in Oude Tonge, the Netherlands. Further, it is involved in the construction of a PV plant with a peak capacity of 300 MW in the municipality of Talaván, Cáceres, Spain. The company was formerly known as NUR Macroprinters Ltd. and changed its name to Ellomay Capital Ltd. in April 2008. Ellomay Capital Ltd. was founded in 1987 and is based in Tel Aviv, Israel. <<<
Ellomay Capital – A 52-Week High
A renewable energy and power generator and developer in Europe and Israel saw its stock reach its new 52-week high in August. According to Investors Observer, Ellomay Capital Ltd (NYSEAMERICAN:ELLO) is near the top in its sector. It gained a ranking of 73, which implies it scores higher than 73% of stocks. <<<
https://www.yahoo.com/news/whats-solar-energy-rundown-6-171355260.html
>>> SolarEdge Technologies, Inc. (SEDG), together with its subsidiaries, designs, develops, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations worldwide. Its SolarEdge system consists of power optimizers, inverters, communication and smart energy management solutions, and a cloud based monitoring platform. The company's products are used in a range of solar market segments, such as residential, commercial, and small utility-scale solar installations. It also provides pre-sales support, ongoing trainings, and technical support and after installation services; and lithium-ion cells, batteries, and energy storage solutions for various industries, including energy storage systems, residential and commercial solar systems, uninterruptible power supplies, electric vehicles, aerospace, marine, and others. The company sells its products to the providers of solar PV systems; and solar installers and distributors, electrical equipment wholesalers, and PV module manufacturers, as well as engineering, procurement, and construction firms. SolarEdge Technologies, Inc. was founded in 2006 and is headquartered in Herzliya, Israel.
<<<
>>> Nano Dimension Ltd. (NNDM), together with its subsidiaries, provides additive electronics in Israel and internationally. Its flagship product is the proprietary DragonFly lights-out digital manufacturing system, a precision system that produces professional multilayer circuit-boards, radio frequency antennas, sensors, conductive geometries, and molded connected devices for prototyping through custom additive manufacturing. The company also provides nanotechnology based conductive and dielectric inks; and DragonFly and Switch software to manage the design file and printing process. It markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. The company was founded in 2012 and is headquartered in Ness Ziona, Israel.
<<<
>>> Gamida Cell Ltd. (GMDA), a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
<<<
>>> BiondVax Pharmaceuticals Ltd. (BVXV), a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel. <<<
>>> Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
https://www.biondvax.com/2020/02/preliminary-data-from-nih-niaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials/
Data published on Clinicaltrials.gov
Jerusalem, Israel – February 5, 2020 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax’s M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M-001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.
Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientific Officer, commented, “We are grateful for the opportunity to collaborate with NIAID and thank them for their professionalism and partnership. This was M-001’s first clinical trial in the US under the FDA’s Investigational New Drug program (IND). Data from this Phase 2 trial confirm results from six previously completed clinical trials of M-001. BiondVax’s universal flu vaccine candidate was found to be safe, well tolerated and induce statistically significant cellular immune responses.”
The Phase 2 clinical trial was conducted by NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs). The trial enrolled 120 participants aged 18 to 49 years at the following VTEU sites: Baylor College of Medicine in Houston, Texas; the University of Iowa in Iowa City, Iowa; and Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. Individuals were randomly assigned to receive either two doses of M-001 or two doses of a placebo, with the doses spaced three weeks apart. Later, near the beginning of the 2018/19 flu season, all participants were immunized with a currently marketed quadrivalent seasonal influenza vaccine. Laboratory analyses of vaccine immunogenicity were performed at the Baylor College of Medicine and Saint Louis University (St. Louis, Missouri) VTEU sites and at BiondVax Pharmaceuticals.
The published data are available at
https://clinicaltrials.gov/ct2/show/NCT03058692. The trial was supported through NIAID awards #HHSN272201300016I, HHSN272201300015I, HHSN272201300020I, and HHSN272201300021I.
In parallel, BiondVax’s pivotal, clinical efficacy, Phase 3 trial in Europe, involving 12,463 older adults, is ongoing. Results of that trial are expected by the end of 2020.
About BiondVax
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax’s proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 7 completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please visit www.biondvax.com.
<<<
>>> Israel Tech ETF Celebrates A Milestone In Style
Benzinga
January 22, 2020
The BlueStar Israel Technology ETF (NYSE: ITEQ), the first exchange traded fund to one of the world's best ex-Asia, ex-U.S. technology scenes, is celebrating an important milestone, having recently topped $100 million in assets under management.
Crossing that much ballyhooed asset level is confirmation for ITEQ, which debuted in 2015. It's confirmation that investors are responding to the investment thesis offered by Israel's burgeoning technology landscape, one widely supported by the emergence of cybersecurity as a significant driver of technology sector performance.
ITEQ follows the BlueStar Israel Global Technology Index. That benchmark “includes Israeli companies, irrespective of listing venue, operating in industries ranging from information technology to biotechnology, defense and security technology, and clean energy technology,” according to BlueStar.
Why It's Important
Crossing assets under management milestones is nice for ETFs, particularly those issued by smaller providers and those with refined investment concepts. What should be important to advisors and investors is the credibility and potential of the fund's investment thesis.
ITEQ has plenty of that. Over the past year, ITEQ is higher by almost 41%, making the 14.90% returned by the MSCI Israel Index over that span seem paltry by comparison.
ITEQ's 12-month run also dispels the notion that there haven't been any ex-US developed market opportunities worth seizing. Speaking of ex-U.S. developed markets, ITEQ is beating the MSCI EAFE Index, of which Israel is a small part, by a margin of more than 3-to-1 over the past year.
Importantly, ITEQ is bringing some flair to the $100 million, having surged 8.51% since the start of this year.
What's Next
Betting against ITEQ would appear premature at this point, if not ill-fated. With cloud, cybersecurity and semiconductor stocks expected to perform well this year, ITEQ is well-positioned to benefit from those trends with a more than 60% weight to software and chip makers.
Then there is consolidation, ITEQ is chock full of would-be buyers and potential acquisition targets at a time of expected consolidation in Israel's technology sector.
“The past decade has been very good to Israel's high-tech industry, which saw 1,210 mega-deals amounting to 385 billion shekels ($111 billion), high-tech industry data research firm IVC-Meitar said this week,” reports Israel Hayom.
<<<
Israel Aerospace Industries -
https://www.ainonline.com/aviation-news/aerospace/2020-04-27/uv-c-light-system-eliminates-covid-19-aircraft-cabins
>>> A UV-C light system will soon be available for disinfecting aircraft interiors, according to Israel Aerospace Industries (IAI), which has been fast-tracking deployment of the technology to combat Covid-19 infection in hospitals. According to the company, the robot-based system is suitable for use in any size of aircraft, having already been tested in a widebody cargo airliner and a helicopter.
The equipment uses a 254-nanometer electromagnetic wave that is shorter than a visual wavelength and longer than an x-ray wavelength. Research has proven its ability to kill any germ or virus, IAI said.
In an aircraft, the robot can move between seats in straight lines and lights on electronically-controlled arms move across all exposed surfaces, such as seats and other cabin fittings. Unexposed surfaces beneath those items would still have to be manually cleaned with chemicals.
For an airliner, the 12-inch-wide robot can move up and down standard aisles between seats. In a smaller aircraft, such as a business jet, one or more stationary units, which were originally designed for hospital rooms, would be deployed.
According to an IAI spokesman, it would take between 30 and 40 minutes to disinfect a widebody aircraft. He said the company remains “a few months” away from being able to deliver the equipment to the aviation sector and is currently exploring what regulatory requirements would apply to its use.
IAI expects to market the system to aircraft operators and maintenance, repair, and overhaul providers. It has yet to announce pricing for the equipment. The company started work on the technology soon after the outbreak of the Covid-19 pandemic. In March, it demonstrated the system in two Israeli hospitals.
<<<
NSO Group - >>> Inside the secretive Israeli spyware startup scene, where the notorious NSO Group has spawned a web of companies that hack into devices
by Becky Peterson
Sept. 6, 2019
Business Insider
https://markets.businessinsider.com/news/stocks/israel-offensive-cybersecurity-world-funded-by-nso-group-2019-9-1028504908
The Israeli cybersecurity firm NSO Group has been accused of selling sophisticated digital surveillance technology to Saudi Arabia and other countries that have allegedly used it to attack dissidents and journalists.
Despite the controversy, the company is extremely profitable.
NSO Group's founders and alumni have spawned a web of more than a dozen similar startups, many of which operate in secret, that sell attacks against routers, computers, smart speakers, and other digital devices.
Spend some time in the shadowy world of companies that sell "offensive cyber capabilities" — secret tools that let you hack into phones, computers, and other digital devices to spy on their users — and one outfit looms large.
It sits at the center of a bustling but discreet ecosystem of startups based in Israel that specialize in bypassing, undermining, and counteracting the security features of our digital environment, granting clients in some cases nearly unrestricted access to the texts, calls, and conversations of almost anyone they choose.
There are more than a dozen such companies in Israel, according to investors and employees in the space, though many of them are operated in stealth by founders who have left miraculously little trace of their existence on the internet.
And chief among them is NSO Group, the largest company at the cutting edge of offensive cybersecurity.
NSO Group's founders say its technology, which focuses on compromising smartphones, is designed with the noble purpose of helping governments combat terrorism and crime.
But the startup became the target of international outrage this year following allegations that its software, called Pegasus, was used by a rogues' gallery of countries including Saudi Arabia, the United Arab Emirates, and Mexico to attack reporters, dissidents, and political targets.
But as a startup, NSO Group is a runaway a success. It has been valued at $1 billion — a fortune in the Israeli tech environment, where the most successful companies get acquired for less than $500 million. And it's wildly profitable, Business Insider can report: It made $125 million in profit last year.
All that money has spawned a new web of highly specialized startups funded by NSO Group's founders and investors, known in tech circles as "the NSO Mafia," which sell niche tools to penetrate WiFi routers, home speakers, and other devices.
These companies often describe their wares as "lawful interception" or "intelligence" tools, though this hardly tells the full story. They all sell tools that take devices and turn them against their users to secretly spy without leaving a trace.
Whatever you call this technology, business is booming. Governments and law enforcement agencies around the world are paying millions of dollars. And startups both inside of Israel and out are ready to sell.
<<<
>>> Else Nutrition Holdings Inc. Announces Dr. Jon A. Vanderhoof – Former Vice President, Global Medical Affairs at Mead Johnson Nutrition
Appointed to Advisory Board
October 23, 2019
https://finance.yahoo.com/news/else-nutrition-holdings-inc-announces-100000068.html
VANCOUVER, BC / ACCESSWIRE / October 23, 2019 / ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY) (OTCQB: BABYF) ("Else" or the "Company"), a company focused on developing and marketing a real alternative to dairy-based infant nutrition, is pleased to announce that effective October 1, 2019, Dr. Jon A. Vanderhoof has been appointed to the Advisory Board of Else Nutrition GH Ltd., the Company's operating company which is located in Israel..
"We are extremely pleased to add Dr. Vanderhoof's experience and insights to the Else Nutrition Team. His extensive expertise, particularly in children's health and nutrition will be of tremendous benefit to our company and our customers," said Hamutal Yitzhak, CEO of Else Nutrition. She added, "His passion for improving children's health perfectly complements our vision as we move our product towards commercialization."
"The opportunity to join Else Nutrition in their vision to create clean-label, and nutritious plant-based alternatives for infants, toddlers and children is extremely exciting. Many of today's parents are demanding all-natural, plant-based solutions free of antibiotics, GMO, and hormones, for their children's nutrition. Careful formulation and scientific and clinical evaluation of such products are essential to ensure their safety and efficacy," said Dr. Vanderhoof. He added, "Else Nutrition's breakthrough formulation will provide the safety and assurance parents need to optimize their child's health and well-being, and I look forward to helping extend this impact."
Dr. Vanderhoof is a pediatric gastroenterologist in at Boston Children's Hospital, Senior Lecturer in Pediatrics at the Harvard Medical School, and Professor Emeritus of Pediatrics at the University of Nebraska College of Medicine. He was the first Chief of Pediatric Gastroenterology and Nutrition at the University of Nebraska Medical Center and served as Chair of Pediatrics at Creighton University. Dr. Vanderhoof was Vice President, Global Medical Affairs and Chief Medical Officer, for Mead Johnson Nutrition from 2002 to 2011. Dr. Vanderhoof received his medical degree from the University of Nebraska College of Medicine, completed his fellowship in Pediatric Gastroenterology and Nutrition at the University of California at Los Angeles, and has been in practice for over 20 years.
Dr. Vanderhoof has published over 200 peer-reviewed papers, reviews and literature in various areas of pediatric gastroenterology and nutrition. He served as President of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and on the editorial boards of numerous scientific and clinical journals. He has lectured widely both nationally and internationally on a variety of issues related to all areas of pediatric gastrointestinal disease and nutrition. Dr. Vanderhoof received the Shwachman Award in 2001 from the North American Society of Pediatric Gastroenterology and Nutrition, the highest award given in the field of Pediatric Gastroenterology in North America.
About Else Nutrition Holdings Inc.
The Company is a food and nutrition company focused on research, development, manufacturing, marketing, sale and/or license of innovative plant-based food and nutrition products to the infant, toddler, children and adult markets. Its revolutionary 100% plant-based non-soy alternative to dairy-based baby formula received the "Best Health and Diet Solutions" award in the Global Food Innovation Summit in Milan in May 2017. For more information, visit: elsenutrition.com.
For more information, contact:
Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E:hamutaly@elsenutrition.com
P: +972(0)52-447-9931
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
<<<
>>> Else Nutrition Receives Favorable Regulatory Assessment Ahead of U.S. Market Launch
ACCESSWIRE
December 16, 2019
https://finance.yahoo.com/news/else-nutrition-receives-favorable-regulatory-110000738.html
VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / December 16, 2019 / ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY, OTCQB: BABYF) ("Else" or the "Company"), a developer of plant-based alternatives to dairy-based baby nutrition, announces that it has received a favorable regulatory assessment of its toddler formula ingredients from EAS Consulting Group, LLC, which conducted a preliminary review of the Else formula in view of the FDA (Food and Drug Administration) requirements.
With vast, global expertise in regulatory approvals, and specialty in FDA requirements, EAS has unique experience and capability pertaining to the introduction of food, drinks and new infant formulas.
"The EAS Infant Formula Team has confirmed that Else toddler formula intended to be marketed in the U.S. meets the regulatory requirements for general food as required for a toddler formula," stated Dr. Fabiana Bar-Yoseph, Else's Director of Clinical Development, Regulatory and Scientific Affairs. She added, "This regulatory validation marks a significant step as we look to bring a nutritious, plant-based toddler formula to the U.S. market."
Else Nutrition's 100% plant-based toddler formula is set to launch in the U.S. market in the second quarter of 2020.
About Else Nutrition Holdings Inc.
The Company is a food and nutrition company focused on research, development, manufacturing, marketing, sale and/or license of innovative plant-based food and nutrition products to the infant, toddler, children and adult markets. Its revolutionary 100% plant-based non-soy alternative to dairy-based baby formula received the "Best Health and Diet Solutions" award in the Global Food Innovation Summit in Milan in May 2017. For more information, visit: elsenutrition.com.
About EAS Consulting Group, LLC (EAS)
Headquartered in Alexandria, VA with consultants and auditors located strategically throughout North and South America, Europe, and various Pacific Rim counties, EAS Consulting Group is a sought-after expert in regulatory matters, assisting firms with highly technical submissions such as GRAS, DMF, NDI, ANDA, 510(k) and others, as well as the development of quality systems, label reviews, structure-function claims, GMP audits, and US Agent assistance and more. EAS Consulting Group, LLC (EAS) specializes in Food and Drug Administration (FDA) regulatory matters.
<<<
>>> Will an Israeli plant-based infant formula go mainstream?
‘It is a near perfect alternative to breastmilk,’ says Else Nutrition’s (BABYF) cofounder about the almond-buckwheat product heading to market in 2020.
Israel 21 c
By Lauren Izso
NOVEMBER 24, 2019
https://www.israel21c.org/will-an-israeli-plant-based-infant-formula-go-mainstream/
Providing an infant with proper nutrition seems like a no-brainer: Breastmilk or cow’s milk. But what if a child is allergic? Lactose intolerant? Until now, there hasn’t been a good alternative.
Else Nutrition, a Tel Aviv-based company, hopes to solve this dilemma for infants and toddlers.
While Else was founded in May 2018, the product has been in research-and-development for five years. The company of only 10 employees has huge plans for expansion in the future.
Else Nutrition cofounder Hamutal Cohen Yitzhak. Photo: courtesy
Hamutal Cohen Yitzhak, one of the cofounders, says the plant-based formula composed of almond milk and buckwheat will launch on the market next year.
“It is a near perfect alternative to breastmilk,” she tells ISRAEL21c.
Yitzhak and the company’s other cofounders launched Else mainly out of their own pockets. They each have backgrounds in the infant nutrition industry in Israel. Yitzhak was previously Israel’s category manager for Similac infant formula at Abbott Labs.
Born out of a granddaughter’s need
The story begins with cofounder Uriel Kesler. His 10-month-old granddaughter was rejecting breastmilk and cow’s milk, and even a special hypoallergenic formula.
“She was allergic to everything the industry could offer her because she couldn’t consume milk or soy,” recalls Yitzhak.“She was vomiting up almost everything she was consuming, and she had respiratory issues as a result.”
At the time, Yitzhak and Kesler had been working together for nearly a decade developing baby snacks.
They began experimenting to find a solution for Kesler’s granddaughter, and quickly found substantial similarities in the makeup of almonds to breast glands. Once they gave the child almond milk, her health began to improve.
But almonds alone did not provide the balance of nutrients a toddler needs to develop properly.
“We had a significant gap in terms of proteins and carbohydrates. So, we searched for another plant that could bring the full amino acid profile of protein. And we found buckwheat,” Yitzhak explains.
“The combination allowed us to imitate breastmilk composition in terms of nutritional value.”
Vegan and healthful
While the main target market includes infants and toddlers with an intolerance to mainstream formulas, Else is “absolutely” an alternative for parents who choose a vegan lifestyle and want their babies to have a plant-based diet as well, Yitzhak says.
“’Vegan,’ however, is not a synonym for ‘healthy.’ You can have a vegan product that is intensely processed and that has many ingredients that are not good for you. Our product is plant-based, vegan and also extremely healthy and all natural,” she says.
“It will take time, but we are going to educate people about this.”
Childcare expert and daycare owner Hagit Miller tells ISRAEL21c that there is no perfect alternative to breastmilk.
“But for those who choose not to breastfeed [or cannot breastfeed], there must be an option that provides a complete proper nutritional diet” without supplements, Miller says.
Up until now, the alternatives have been far less than perfect.
“There is scientific data that proves that soymilk can damage the hormone system,” Yitzhak says.
Soymilk was once the number one formula replacement. Another company is trying to develop a similar product using rice but was unable to eliminate arsenic from the composition.
Coming to online stores first
Else Nutrition has spent the last five years developing and testing the product, and Yitzhak says it will hit online stores in North America in 2020, and a few months later in Europe.
The formula will cost around $27-$30 for 23 ounces of powder.
Yitzhak anticipates that Else eventually will be sold in health food stores, and even in supermarkets one day.
The plant-based baby formula already has claimed several awards including “Best health and diet solution” at the Global Food Innovation Summit in 2017 in Milan.
Else Nutrition was a finalist at the startup competition at FoodTechIL in September, and at the Foodbytes London pitch competition in November.
Recently, a group of Canadian investment brokers from Canaccord Genuity Corporation invested $5.7 million in Else Nutrition. As a result, the company is now listed on the Toronto Stock Exchange, one of the biggest in the world.
Now the company is focused on mass production in order to prepare for next year’s launch. According to Yitzhak, this is just the beginning.
“We hope to develop products based on this concept for the entire family from infants to the elderly.”
<<<
>>> Israeli biotechs and Chinese biotechs are both problematic for investors—but for different reasons.
With Chinese biotechs, foreign investors’ main problem is that there they aren’t actual shareholders of the underlying company, so they have no BoD representation and they have insufficient legal protection from simple expropriation.
With Israeli biotechs, investors’ main problem is that the science is often dubious. Compared to the US, Israel does not have as well-established a biotech VC community, so Israeli companies that ought to be in the VC stage end up trading on the TASE or Nasdaq. <<<
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152790626
>>> CyberArk Software Ltd. (CYBR), together with its subsidiaries, provides software-based security solutions and services for organizations to safeguard and monitor their privileged accounts. The company's solutions include Core Privileged Access Security for risk-based credential security and session management with add-on options for least privilege server and domain controller protection; Application Access Manager for secrets management for applications, tools, containers, and DevOps; and Endpoint Privilege Manager for least privilege and credential theft protection for workstations. It also provides Sensitive Information Management solution; and software maintenance and support, and professional services. The company offers its products to financial services, manufacturing, insurance, healthcare, energy and utilities, transportation, retail, technology, and telecommunications industries, as well as government agencies through direct sales force, as well as distributors, systems integrators, value-added resellers, and managed security service providers. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, Latin America, and Canada. CyberArk Software Ltd. was founded in 1999 and is headquartered in Petach Tikva, Israel.
<<<
>>> Wix.com Ltd. (WIX) develops and markets an Internet service that allows users to create Web content in North America, Europe, Latin America, Asia, and internationally. The company offers Wix Editor, a drag-and-drop visual development and Website editing environment platform; Wix ADI that enables users to create a Website for their specific needs; and Wix Code to create Websites and Web applications. It also provides Ascend by Wix, which offers its users access to a suite of approximately 20 products or features enabling them to connect with their customers, automate their work, and grow their business; Wix Logo Maker that allows users to generate a logo using artificial intelligence; Wix Answers, a support infrastructure enabling its users to help their users across various channels; and Wix Payments, a payment platform, which helps its users receive payments from their users through their Wix Website. In addition, the company offers various vertical-specific applications that business owners use to operate various aspects of their business online. Further, it provides a range of complementary services, including App Market that offers its registered users the ability to install and uninstall a range of free and paid Web applications; Wix Arena, an online marketplace that brings users seeking help in creating and managing a Website, together with Web experts; and Wix App, a native mobile application, which enables users to manage their Websites and Wix operating systems. As of December 31, 2018, the company had approximately 142 million registered users and 3,983,415 premium subscriptions. Wix.com Ltd. has a strategic partnership with NTT Town Page Corporation. The company was formerly known as Wixpress Ltd. Wix.com Ltd. was founded in 2006 and is headquartered in Tel Aviv, Israel.
<<<
>>> Mellanox Technologies, Ltd. (MLNX), a fabless semiconductor company, designs, manufactures, markets, and sells interconnect products and solutions. Its products facilitate data transmission between servers, storage systems, communications infrastructure equipment, and other embedded systems. The company offers InfiniBand solutions, including switch and gateway integrated circuits (ICs), adapter cards, cables, modules, and software, as well as switch, gateway, and long-haul systems; and Ethernet solutions, such as Ethernet switch products and Ethernet adapters for use in enterprise data center, high-performance computing, embedded environments, hyperscale, Web 2.0, and cloud data centers. It also provides adapters to server, storage, communications infrastructure, and embedded systems original equipment manufacturers (OEMs) as ICs or standard card form factors with PCI express interfaces; and switch ICs and systems to server, storage, communications infrastructure, and embedded systems OEMs to create switching equipment. In addition, the company supports server operating systems, including Linux, Windows, AIX, HPUX, Solaris, and VxWorks. It sells its products through its direct sales force, a network of sales representatives, and independent distributors. The company operates in the United States, China, Europe, rest of Americas, and rest of Asia. Mellanox Technologies, Ltd. was founded in 1999 and is headquartered in Sunnyvale, California.
<<<
>>> Is NovoCure a Buy?
Investors in the cancer-focused medical device company have enjoyed strong returns already. Is it too late to hop on board?
Motley Fool
Brian Feroldi
Dec 24, 2018
https://www.fool.com/investing/2018/12/24/is-novocure-a-buy.aspx
Billions of dollars have been spent on research and development in the battle against cancer. Unfortunately, cancer still claims more than half a million lives in the U.S. alone each year.
Novocure (NASDAQ:NVCR) is on a mission to give patients with cancer a fighting chance. This innovative medical-device company is harnessing the power of physics to approach cancer treatment from a unique perspective.
The company discovered that electric fields can be manipulated to inhibit cell division in cancerous tumorous. Novocure calls this new method of treatment tumor treating fields, or TTFields for short, and is pushing hard to convince healthcare providers to add this new weapon to their arsenals. Its early success at winning over skeptics has led to explosive revenue growth, and its share price has soared.
Is Novocure a buy today, or is it too late to get in?
The technology
Nearly two decades ago, Novocure's founder discovered that electric fields could be used to inhibit division in certain types of cells. The company also figured out that tuning an electric field to a specific frequency would disrupt division in certain types of cells without having any impact on other types of cells (Novocure's Bill Doyle explained this process in great detail during a Ted Talk).
A key benefit of this technology is that TTFields could be fine-tuned to disrupt cell division in cancerous tumors while leaving nearby healthy cell alone. This allows TTField therapy to be administered with minimal side effects.
Novocure took its knowledge of TTFields and created a portable electric field generator called Optune, which won FDA approval to treat recurrent glioblastoma in 2011. Glioblastoma is an especially aggressive form of brain cancer that has a very low, five-year survival rate. Thankfully, Novocure showed last year that using Optune in combination with current standard-of-care treatments led to improved survival rates.
The opportunity
Novocure has launched Optune in the U.S., Europe, and Japan. The company's business model is to bill for Optune on a monthly basis. That's why a key metric for investors to watch is the number of active users that are on Optune at any given time.
Demand for Optune has grown steadily as providers, payers, and patients became more comfortable with the technology. In turn, Novocure's revenue has soared.
Metric 2015 2016 2017 2018*
Active patients 605 1,091 1,834 2,252*
Revenue $33.1 million $82.9 million $177 million $178 million*
*DATA AS OF SEPT. 30, 2018.
Glioblastoma is a rare form of cancer, so the company's current market opportunity for Optune is limited. However, the company believes that TTFields could also be useful in treating a wide variety of solid-tumor cancers down the road. Management is investing aggressively in R&D in an effort to capitalize on that potential.
How big could the company's total addressable market grow if TTFields are shown to be effective in other types of cancer? Here's an overview of Optune's label expansion potential:
Indication Status Potential Annual Patient Population in Target Markets
Glioblastoma Approved 14,000
Mesothelioma Pending approval 13,000
Brain Metastases Phase 3 trial end 2020 258,000
Lung cancer Phase 3 trial ends 2021 659,000
Pancreatic cancer Phase 3 trial ends 2022 223,000
These numbers are enormous when compared to the company's current active patient count of just 2,252. If Novocure can win approval in any of these indications, then its upside potential is truly massive.
Digging into the financials
Novocure has operated at a loss since its founding. The company is still losing money today, even with its considerable revenue growth. A key reason why is that the company has been plowing money into growing its commercial team and funding its late-stage R&D programs. If any of those clinical trials result in label expansion claims, that will prove to be money well spent.
Novocure's net loss for all of 2018 should come in right around $60 million or so. Funding that loss won't be a problem because the company had more than $226 million in cash in the bank as of the end of September.
Market watchers predict that the company's net loss will shrink considerably in 2019. If that happens, the company shouldn't have to tap investors for additional capital anytime soon.
Is NovoCure a buy?
For NovoCure to be a successful investment from here, it must be able to win label expansion claims into other types of cancer. Since regulatory success is never guaranteed, this isn't a good stock for risk-averse investors to buy.
Personally, I think the odds of Optune winning label expansion claims are quite good given that the company has already shown clinical success in treating brain cancer, and Optune's side effects are so minimal. That's why I decided to become a shareholder.
If you have a strong stomach for risk and want a stock that could turn into a home run, NovoCure might be for you.
<<<
>>> Mysterious Private Jet Flight From Israel to Saudi Arabia Has Media Guessing
Bloomberg
By Alisa Odenheimer
October 24, 2019
https://www.bloomberg.com/news/articles/2019-10-24/mysterious-flight-from-israel-to-saudi-arabia-has-media-guessing?srnd=premium
A private jet took off from Ben-Gurion International Airport near Tel Aviv on Tuesday evening, landed for a few minutes in Amman, then proceeded to the Saudi capital, Riyadh, leaving Israeli media guessing who was on the plane.
Yossi Melman, who writes for the Maariv daily, tweeted that Prime Minister Benjamin Netanyahu or Mossad spy chief Yossi Cohen may have been on board the flight to the Arab kingdom, which has no diplomatic ties with Israel, possibly to discuss the situation in Syria.
Haaretz’s Avi Scharf tweeted that the trip was “EXtra rare.” He noted that U.S. Secretary of Defense Mark Esper was in Riyadh around the same time and questioned whether the U.S.-registered jet had brought an official for a “snap trilateral.”
@avischarf
EXtra rare: Israeli biz landed Riyadh ???? overnight for 1 hr, then back (n556us cl-60)
Unrelated (prob), ???? SecDef @EsperDoD was also in the Kingdom yesterday
avi scharf
@avischarf
Replying to @avischarf @EsperDoD
So earlier I said 'prob unrelated', because I thought Esper had already left KSA for Europe, but now I realize he's still in the neighborhood - he just appeared in Baghdad.
Did someone from Israel come for a snap trilateral in Riyadh? I don't know
The jet took off after about an hour in Saudi Arabia and returned to Israel, the Jerusalem Post reported. The same plane has also made trips between Tel Aviv and Cairo in recent months, it said.
Although Israel has no formal relations with Saudi Arabia, ties are gradually warming up, in part due to shared concerns over Iran’s growing influence in the region. In the absence of an Israeli-Palestinian peace deal, most of the cooperation has taken place behind the scenes.
<<<
(perhaps it was the ghost of Mike Harari, lol)
https://en.wikipedia.org/wiki/Michael_Harari
>>> Foamix Pharmaceuticals (FOMX) -
https://finance.yahoo.com/news/3-top-biotech-stocks-major-041721066.html
Foamix Pharmaceuticals is also hopeful of getting to market and has two promising late-stage dermatological drugs in its pipeline. FMX101 targets the treatment of moderate-to-severe acne and has already had its NDA submitted. Management is also hopeful to hear some news from the FDA very soon. FMX103 targets moderate-to-severe rosacea, which has much less competition than competing acne treatments in the marketplace. It also made it through clinical three trials and an FDA decision is expected somewhere in the middle of 2020.
Cantor analyst Louise Chen reported on Foamix’s presentation at the firm's healthcare conference in early October, noting: "After listening to FOMX's presentation, we continue to look forward to the potential launches of FOMX's two late-stage products in the 2019/20 timeframe. We expect approval for the company's lead product candidate FMX101 for the treatment of moderate-to-severe acne." Chen rates FOMX an Overweight with $15 price target, which implies huge upside to the current share price of $2.80.
Research firm Cowen recently pointed out that Foamix is currently building out its sales force in anticipation of the potential launch of both dermatology candidates. Based off its price target of $30, it is effectively twice as bullish as Cantor.
Like many development-stage biotech firms, Foamix is in a precarious financial position and has accumulated a deficit above $200 million to bring these and related drugs to market. But with any positive FDA news, the share price will likely soar and open the gateway to plenty of opportunities to raise growth capital.
Returning again to TipRanks’ consensus analyst estimates, FOMX has received 3 "buy," ratings in the last three months, while the 12-month average price target lands at $17.00, or more than 500% ahead of the current share price.
<<<
>>> Foamix Pharmaceuticals Ltd. (FOMX), a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
<<<
Eviation - >>> Electric Planes to Debut for Airline Serving Nantucket, Vineyard
Bloomberg
By Tara Patel
June 18, 2019
https://www.bloomberg.com/news/articles/2019-06-18/electric-plane-maker-eviation-clinches-first-customer-cape-air
Israeli venture-backed aircraft maker predicts supply crunch
‘We’re talking to everyone’ on future sales, Eviation CEO says
EVIATION AIRCRAFT (EVTNF)
Electric-plane company Eviation Aircraft Ltd., which just signed up its first customer, predicts that in a few years it may not be able to keep up with orders.
“We’ll have a supply issue, not a demand issue,” Chief Executive Officer Omer Bar-Yohay said in an interview at the Paris Air Show. The founder of the Israeli venture capital-backed developer said U.S. regional airline Cape Air has agreed to buy a “double-digit” number of planes. The carrier flies some 88 Cessna turbo-props on routes such as Boston to Martha’s Vineyard and New York to Nantucket.
Eviation was showcasing a prototype, transported in pieces to the biennial exhibition, and is “talking to everyone” about future sales, said Bar-Yohay. Prospective customers include major U.S. carriers like United Continental Holdings Inc. and JetBlue Airways Corp., which are interested in planes to feed hubs, he said.
Eviation’s plane, the Alice, is one of a host of electric models at the design stage, and its nine-passenger capacity and 650-mile range from a single charge could give it an edge in the commuter market, currently served by a variety of light aircraft. Interest in electric planes is growing as the aviation industry comes under criticism for increasing emissions of greenhouse gases.
Read: Stratospheric: What Happens to Airline Emissions Under Self-Rule
Eviation is planning a first flight later this year in the U.S., followed by the assembly of more planes in Arizona and Washington state and certification around 2021.
“We’re a bit ahead of the pack but I have no doubt others are coming,” Bar-Yohay said, adding that taking on a customer like Cape Air will also entail developing charging and maintenance infrastructure.
“The hurdles aren’t just about getting the plane out the door, but everything else that goes with them,” he said. “We need an environment to support the plane and trained engineers and mechanics.”
Aircraft Economics
Eviation contends its plane makes economic sense: Running costs for the Alice will be about $200 per flight hour versus $1,000 for a turboprop. The Alice will be slower than some conventional craft, with a cruising speed of 240 knots (276 miles per hour), half the pace of modern business jets but not far short of some turboprop models.
The company is targeting “middle mile” commutes like Paris to Toulouse, Oslo to Trondheim in Norway and San Jose to San Diego.
Read: Airbus May Make the Next Version of Top-Selling Jet a Hybrid
Based in Kadima, near Tel Aviv, Eviation was founded in 2015 by a team of aviation and technology specialists. It’s one of about 100 different electric-aircraft programs in development worldwide, up 30% since 2017, according to Roland Berger, a consulting firm.
Zunum Aero, backed by Boeing Co. and JetBlue, aims to bring a hybrid-electric commuter model to market by 2022, while MagniX Technologies Pty is developing a propulsion system for an all-electric plane with a similar date in mind. In September, it announced a successful ground test of a 350-horsepower motor attached to the nose section of a Cessna test rig.
Joby Aviation Inc. is aiming smaller, targeting the air-taxi market with a plane that would carry four passengers, travel 150 miles and fly at a few thousand feet. Unlike the Alice, it wouldn’t be pressurized. Uber Technologies Inc. has said it’s also working on a flying taxi as an extension of its ride-sharing product that would take off and land vertically and reach the market by 2023.
At the other end of the scale, Easyjet Plc has partnered with U.S.-based Wright Electric to develop a full-sized battery-powered airliner within a decade for flights of less than two hours, enough to link London with Paris or Amsterdam.
Siemens AG, Airbus SE and Rolls-Royce Holdings Plc are working on a hybrid-electric propulsion system, the E-Fan X, that would also power a relatively large aircraft. Roland Berger predicts that the first 50-seat hybrid airliner will enter fare-paying service by 2032.
<<<
Eviation -- >>> All-electric jet firm Eviation announces US regional airline as first customer, predicts delivery in 2022
CNBC
JUN 18 2019
by David Reid
https://www.cnbc.com/2019/06/18/all-electric-jet-firm-eviation-announces-us-airline-as-first-customer.html
Venture capital-backed Eviation is developing a nine-seat electric aircraft.
The firm sees regional travel as being under served by aviation.
A prototype of its electric plane has been unveiled at the Paris Air Show.
Eviation chief executive Omer Bar-Yohay reveals future plans for his company’s nine-seat electric plane at the 2019 Paris Air Show.
PARIS — The Israeli start-up Eviation announced at the Paris Air Show that U.S regional airline Cape Air is to buy its electric aircraft.
Eviation is developing a nine-passenger aircraft designed to fly up to 650 miles at around 240 knots (276 miles per hour). A commercial jet would cruise around 500 miles per hour. The electric plane — called Alice with a prototype being unveiled at the show this week — is designed for the sort of distances usually conducted by train.
Cape Air is set to buy a “double-digit” number of the plane which has a list price of around $4 million each. It’s expected that any customer would be able to negotiate a smaller figure.
The company’s chief executive, Omer Bar-Yohay, told a press conference Tuesday that he expected to receive certification by late 2021, with deliveries predicted for 2022.
“This aircraft is not some future maybe. It is there, ready and waiting,” he said.
Bar-Yohay cited the contributions from Honeywell who built the plane’s controls as well as Siemens, and magniX who provided the electric motor and related functions.
A rendered image of the Eviation Alice. An electric aircraft designed to take 9 passengers up to 650 miles at 240 knots.
Source: Eviation
Bar-Yohay said the plane would now travel to Arizona in the United States where it would be flight tested before being put forward for certification with the U.S. FAA (Federal Aviation Administration).
The CEO added the plane should satisfy FAA concerns that it might create a backlog of training for pilots, as it was “probably one of the easiest planes to fly,” adding “this is one of the specimens that the FAA wants to see happen.”
The Eviation boss said that eventually, future planes would be built in the United States.
Most of Eviation’s funding is from Clermont Group, the private investment fund of Singapore-based billionaire Richard Chandler. Clermont has given Eviation $76 million in exchange for a 70% stake in the company, according to a filing with the U.S. Securities and Exchange Commission dated January 3.
In a in a letter to staff, Chandler said commercial-scale electric aircraft would “change the culture of air travel for future generations,” and that the aerospace industry was entering a new era.
“45% of all flights are under 500 miles – approximately the distance from London to Zurich, or New York to Detroit. This puts almost half of all global flights within the range of an electric motor.”
Clermont also owns and funds magniX, the firm that manufactures the three electric motors that provide the aircraft with roughly 900 kilowatts of power. Bar-Yohay claimed if there was a problem with the two wing engines, it could continue flying on the rear rotor only.
The CEO of magniX, Roei Ganzarski, also attended the launch, telling CNBC it was “exciting to see a dream come true.”
Ganzarski said his engines would be split between new clean sheet aircraft such as the Eviation and retrofitting existing small aircraft.
<<<
>>> Radware Ltd. develops, manufactures, and markets cyber security and application delivery solutions for applications in physical, virtual, cloud, and software defined data centers worldwide. The company offers DefensePro, a real-time network attack prevention device; AppWall, a Web application firewall; and DefenseFlow, a cyber-command and control application. It also provides Alteon D Line, an application delivery controller/load balancer for Web, cloud, and mobile based applications; and LinkProof NG, a multi-homing and enterprise gateway solution for connectivity of enterprise and cloud-based applications. In addition, the company offers Security Updates Subscription, which provides security updates to protect customers against the latest threats; ERT Active Attackers Feed that provides customers with information pertaining to attack sources recently involved in DDoS attacks; Alteon Global Elastic License that captures application lifecycle for large ADC deployments; APSolute Vision, a management and monitoring tool for company's application delivery and cyber security solutions; and MSSP Portal, a DDoS detection and mitigation service portal. Further, it provides Cloud DDoS Protection Service, which offers a range of enterprise-grade DDoS protection services in the cloud, as well as technical support, professional, managed, and training and certification services to its customers. The company sells its products primarily to independent distributors, including value added resellers, original equipment manufacturers, and system integrators. Radware Ltd. was founded in 1996 and is headquartered in Tel Aviv, Israel.
<<<
>>> Aquanomix and AMIAD Water Systems join forces!
January 22, 2018
https://aquanomix.com/aquanomix-amiad-water-systems-join-forces/
AMIAD USA Inc. AND AQUANOMIX JOIN FORCES TO TRANSFORM INDUSTRIAL WATER MANAGEMENT
Charlotte, N.C., (January 22, 2018) … Amiad USA Inc., a global leader in water treatment and filtration solutions, and Aquanomix LLC, a technology leader pioneering the Internet of Things (IOT) in water management, announce a strategic partnership that will transform cooling tower water management.
The two companies will combine their products in GenesisTM– a hardware and software system – provides the user with a real-time risk management platform that offers greater protection for critical cooling systems. The system will increase efficiency, save costs and reduces the risks of biological activity in cooling systems. The product will be available March 1, 2018.
“Symphony GenesisTM is the first system that marries water treatment hardware with optimization software in one easy to use package” said Michael Poth, Amiad USA President. “We anticipate great interest from anyone who treats water in cooling tower installations.”
The partnership will leverage Amiad’s engineering and development capabilities and the revolutionary SymphonyTM cloud-based, water-monitoring platform
Water management programs for cooling tower systems address four key elements: scale, corrosion, microbiology, and fouling. Historically, responsibility for these critical elements has been divided between mechanical and chemical areas of discipline. Chemistry takes care of scale, corrosion, and microbiology control. Mechanical filtration removes fouling components, such as dirt and other airborne particulates, which can act as nutrient sources for microbiological organisms. GenesisTM is the first product to monitor all four elements in a single system.
“By joining forces, we have enabled our customers with an intuitive risk management platform” said Rob O’Donnell, Aquanomix CEO. “We believe this product could become the industry benchmark.”
“We’ve blended data management and proven filtration technology” added Poth. “Genesis will provide critical data to property managers, building owners, and risk managers who can expect to lower their operating costs because they have reduced water and energy use.”
Each partner plays a key role in production and distribution. Amiad makes the complete skids – piping, filtration, pumps, and more – for the system. Aquanomix provides sensors and hardware for the monitoring system and the software. Customers can purchase Symphony GenesisTM through the Aquanomix distribution network. Support for software is through Aquanomix’s Davidson, NC headquarters, and on-site support of the system is provided by both companies.
About Amiad
Amiad USA Inc. is the North American branch of Amiad Water Systems, a leading producer of automatic, self-cleaning water treatment and filtration products and systems. Through its engineering skills and ability to innovate, Amiad provides cost-effective, green solutions for the industrial, municipal, irrigation, oil and gas, and ballast water markets. In these segments, its patented products are being integrated into the core of systems for filtration and water treatment, micro-irrigation, membrane protection, wastewater and potable water treatment, cooling systems, and sea water filtration.
Headquartered in Mooresville, N.C., Amiad USA Inc.provides these solutions through a comprehensive network of distributors to customers throughout North America.
About Aquanomix
Aquanomix is an environmental technology company that delivers water optimization and energy-saving platforms for water-based systems. Aquanomix has pioneered the emerging water reuse market in the U.S. marketplace. The company is best known for its Nexus Number, which delivers the building’s water quality and heat exchanger efficiency data into a single portal, straight to the building’s owners and operators.
Headquartered in Davidson, N.C., Aquanomix developed the SymphonyTM platform to explore, define, and predict intrinsic relationships among environmental, operating, and economic factors that drive cooling water generation through real-time data aggregation and analysis.
<<<
>>> Intec Pharma Ltd. (NTEC), a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
<<<
Mellanox - >>> NVIDIA joins Intel in bidding war for major Israeli chip maker
It might be close to buying Mellanox.
Engadget
Jon Fingas
3-10-19
https://www.engadget.com/2019/03/10/nvidia-enters-bidding-war-for-mellanox/?yptr=yahoo
If you needed any further evidence that NVIDIA is becoming more of a direct competitor for Intel, you might just have it. A Calcalist source claimed that NVIDIA has made an offer to acquire Mellanox, a chip maker best known for its high-performance computing and networking tech. While it's not clear how much NVIDIA has been willing to pay, Reuters insiders said that NVIDIA could pay more than $7 billion -- well past the $6 billion Intel reportedly offered a few months ago.
Mellanox and Intel have declined to comment, while NVIDIA wasn't available for comment on the weekend. Xilinx is also believed to be involved in the bidding, but Reuters believed that NVIDIA is close enough that it could unveil a deal as soon as March 11th.
While the exact reasons for a potential deal aren't clear, NVIDIA would have more than a few incentives to buy Mellanox -- some of which you might notice. It could be most helpful for servers, supercomputers and other situations where you need many processors working in tandem. At the same time, it could also be useful for self-driving cars (where multiple processors may have to coordinate actions), or even ensuring fast connections between multiple GPUs in workstations and gaming PCs.
For Intel, it would be more of a defensive play. Intel and Mellanox have both cornered the market for the InfiniBand technology used to link computer clusters, and this could help keep the technology out of the hands of NVIDIA, AMD and other competitors. It could also help with Intel's ambitions as it eyes quantum computing and other technologies that could depend on very fast connections.
<<<
Name | Symbol | % Assets |
---|---|---|
NovoCure Ltd | NVCR | 7.93% |
Amdocs Ltd | DOX | 7.61% |
NICE Ltd | NICE | 7.33% |
Check Point Software Technologies Ltd | CHKP | 6.92% |
Mellanox Technologies Ltd | MLNX | 6.31% |
Wix.com Ltd | WIX | 5.63% |
CyberArk Software Ltd | CYBR | 5.08% |
Elbit Systems Ltd | ESLT | 4.38% |
SolarEdge Technologies Inc | SEDG | 4.19% |
Ormat Technologies Inc | ORA | 3.96% |
Name | Symbol | % Assets |
---|---|---|
Ituran Location and Control Ltd | ITRN | 2.23% |
Perion Network Ltd | PERI | 2.21% |
Electra Consumer Products Ltd | ECP | 2.20% |
Cellcom Israel Ltd | CEL | 2.12% |
Kornit Digital Ltd | KRNT | 2.09% |
Danel (Adir Yeoshua) Ltd | DANE | 2.03% |
Malam-Team Ltd | MLTM | 2.02% |
One Software Technologies Ltd | ONE | 2.02% |
DarioHealth Corp | DRIO | 2.01% |
Allot Ltd | ALLT | 2.00% |
Name | Symbol | % Assets |
---|---|---|
Wix.com Ltd | WIX | 8.50% |
Bank Leumi Le-Israel BM | LUMI | 7.75% |
NICE Ltd | NICE | 7.07% |
Check Point Software Technologies Ltd | CHKP | 6.70% |
Bank Hapoalim BM | POLI | 6.30% |
Teva Pharmaceutical Industries Ltd ADR | TEVA | 5.23% |
Israel Discount Bank Ltd Class A | DSCT | 3.67% |
CyberArk Software Ltd | CYBR | 3.56% |
Fiverr International Ltd | FVRR | 3.43% |
ICL Group Ltd | ICL | 3.34% |
Name | Symbol | % Assets |
---|---|---|
Wix.com Ltd | WIX | 5.73% |
SolarEdge Technologies Inc | SEDG | 5.44% |
NovoCure Ltd | NVCR | 5.39% |
NICE Ltd ADR | NICE | 5.29% |
Check Point Software Technologies Ltd | CHKP | 5.22% |
Bank Leumi Le-Israel BM | LUMI | 5.07% |
Teva Pharmaceutical Industries Ltd ADR | TEVA | 4.27% |
Bank Hapoalim BM | POLI | 3.76% |
Amdocs Ltd | DOX | 3.71% |
Fiverr International Ltd | FVRR | 3.33% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |